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Neural Regulatory Mechanisms that Link Metabolism and Behavior in 
Caenorhabditis elegans 
Aude Bouagnon 
 
 
Abstract 
The neurotransmitter 5-hydroxytryptamine or serotonin, functions as an indicator of food 
availability and is an ancient mechanism by which invertebrate and vertebrate species 
translate sensory information about food availability and quality to distinct nutrient-
related behaviors and physiologies. Serotonin signaling is influenced by internal and 
environmental signals and coordinates a wide range of behaviors related to nutrient-
status including appetite, reproduction, growth, learning, memory and mood. Despite 
these fundamental roles, the precise mechanisms that link neural serotonin to  
physiologies occurring in distant peripheral tissues remain poorly understood.  
Moreover, little is known about the mechanisms that link internal metabolic signals from 
peripheral tissues to neural serotonin circuits to regulate behavior.  In this work, we 
leverage the experimental advantages of C. elegans to investigate these two distinct yet 
coordinated aspects of serotonin signaling. In chapter I, we examine how neuronal 
serotonin signaling communicates to distant tissues to regulate behaviors like 
movement, development and fat metabolism. In chapter II,III and IV, we identify the 
metabolic, molecular, and cellular components of a novel gut-to-brain regulatory axis 
that links peripheral metabolic signals to serotoninergic circuits that regulate behavior. 
Together, this work highlights the influence that peripheral metabolic signals exert on 
neuroendocrine signaling cascades and offers mechanistic insights into how nutrient 
cues modulate a neuromodulatory mechanism implicated in the control of mood, 
cognition and behavior.  
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Chapter I: Loss of a Neural AMP-Activated Kinase Mimics the 
Effects of Elevated Serotonin on Fat, Movement, and 
Hormonal Secretions 
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Abstract 
 
AMP-activated protein kinase (AMPK) is an evolutionarily conserved master regulator of 
metabolism and a therapeutic target in type 2 diabetes. As an energy sensor, AMPK 
activity is responsive to both metabolic inputs, for instance the ratio of AMP to ATP, and 
numerous hormonal cues. As in mammals, each of two genes, aak-1 and aak-2, encode 
for the catalytic subunit of AMPK in C. elegans. Here we show that in C. elegans loss of 
aak-2 mimics the effects of elevated serotonin signaling on fat reduction, slowed 
movement, and promoting exit from dauer arrest. Reconstitution of aak-2 in only the 
nervous system restored wild type fat levels and movement rate to aak-2 mutants and 
reconstitution in only the ASI neurons was sufficient to significantly restore dauer 
maintenance to the mutant animals. As in elevated serotonin signaling, inactivation of 
AAK-2 in the ASI neurons caused enhanced secretion of dense core vesicles from 
these neurons. The ASI neurons are the site of production of the DAF-7 TGF-b ligand 
and the DAF-28 insulin, both of which are secreted by dense core vesicles and play 
critical roles in whether animals stay in dauer or undergo reproductive development. 
These findings show that elevated levels of serotonin promote enhanced secretions of 
systemic regulators of pro-growth and differentiation pathways through inactivation of 
AAK-2. As such, AMPK is not only a recipient of hormonal signals but can also be an 
upstream regulator. Our data suggest that some of the physiological phenotypes 
previously attributed to peripheral AAK-2 activity on metabolic targets may instead be 
due to the role of this kinase in neural serotonin signaling. 
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Introduction 
AMP-activated protein kinase (AMPK) is a sensor of energy status that is 
conserved from single celled yeasts to humans [1]. At the cellular level, it becomes 
activated in response to deficits in energy availability, such as a rise in the ratio of AMP 
to ATP, to inhibit energy utilizing pathways while activating energy generating pathways 
[1]. AMPK is also a recipient of many hormonal signals and links organism-wide signals 
of energy balance with myriad cellular mechanisms that are differentially regulated 
based on energy availability [2]. While many of the consequences of AMPK activity are 
due to its regulation of substrates in peripheral tissues, activity of hypothalamic AMPK in 
mammals is also thought to contribute to energy balance through modulation of feeding 
behavior [3]. Given its broad effects on energy balance, AMPK is a therapeutic target for 
type 2 diabetes as well as certain cancers [4,5]. Despite the key role of this kinase 
complex in energy balance and its therapeutic relevance, many of the physiological 
consequences of AMPK activity and its upstream inputs and downstream effectors still 
remain poorly understood.  
C. elegans provides a genetically tractable system for studying the physiological 
roles of AMPK in the context of whole animals. In C. elegans as in mammals, AMPK is 
a kinase complex with catalytic a and regulatory b and c subunits [1,6]. Similar to 
mammals, two genes, aak-1 and aak-2, separately encode AMPK’s catalytic a subunit 
[6]. Thus far, roles for aak-2 have been reported in several facets of C. elegans biology 
including the regulation of feeding [7], fat [1,8,9], L1 diapause and nutrient deprivation 
[1,10], dauer maintenance [2,9,11,12], and longevity [3,6,13,14]. In most of these 
processes, the requirement for aak-2 has been attributed to its roles in peripheral 
tissues.  
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As in mammals, 5- hydroxytryptamine (5-HT), serotonin, signaling in C. elegans 
serves as an indicator of food availability [4,5,15,16]. Animals deficient in 5-HT signaling 
due to inactivation of tryptophan hydroxylase, tph-1, the rate limiting enzyme in 
serotonin biosynthesis, exhibit many of the phenotypes seen when animals are 
removed from food [1,6,15]. In turn, treatment of animals with exogenous serotonin 
elicits many of the phenotypes seen when food deprived animals are re-exposed to food 
[6,17– 20]. Beyond simply an indication of food availability, serotonin signaling informs 
on a number of other inputs, including food quality [7,21,22], pathogenicity [22,23], and 
the experience of starvation prior to re-feeding [18,19,24]. For instance, when taken off 
food, C. elegans quickly reduce their feeding, as measured by the pharyngeal pumping 
rate [18], and once again elevate it as they are reintroduced to food. If animals 
experience a period of fasting, they display an even greater increase in feeding rate 
upon re-encountering food [18]. This increased feeding rate can also be induced if well-
fed animals, which already have elevated levels of serotonin signaling relative to food 
deprived animals, are treated with serotonin or fluoxetine, a serotonin uptake inhibitor 
[25]. In another example, as animals deplete their food stores, they move more rapidly, 
presumably to forage for new food resources, and slow their movement once they find 
such resources [17]. If animals are fooddeprived for a period of time before they re-
encounter food, they exhibit a more significant slowing of movement known as 
enhanced slowing. This enhanced slowing is dependent on serotonin signaling since 
animals deficient in serotonin production only partially exhibit the enhanced slowing 
response and addition of serotonin to well-fed animals reduces movement rate [17,26]. 
Thus, serotonin is not simply a binary, on/off indicator of food availability but levels of 
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serotonin signaling allow animals to tune their behavioral and physiological responses 
to food related cues and experiences.  
We previously found that 5-HT secreted from the ADF neurons, a pair of ciliated 
sensory neurons that are known to be responsive to the environment [27], acts on the 
SER-5 serotonergic receptor on the AVJ pair of interneurons to modulate food intake 
rate [7]. Our studies suggested that signaling through SER5, a Gas coupled receptor, 
leads to activation of protein kinase A (PKA) and subsequent PKA-mediated 
phosphorylation of AAK-2 at residue S244 causing inhibition of AAK-2 activity, likely 
through inhibition of phosphorylation at the adjacent T243 residue, equivalent of T172 in 
mammalian AMPK catalytic subunit [7,28]. Thus, loss of AAK-2 activity mimicked the 
very high levels of feeding seen food deprived animals encounter food or well-fed 
animals are treated with additional doses of serotonin.  
Here, we demonstrate that loss of aak-2 mimics the effects of elevated serotonin 
signaling on enhanced fat metabolism, reduced movement, and exit from the dauer 
state. In the context of dauer maintenance, we show that inactivation of aak-2 links 
serotonin signaling to the release of DAF-7, a TGF-b family ligand, and DAF-28, 
encoding an insulin family member, from the ciliated ASI neurons in a cell autonomous 
fashion. While AMPK is often considered a downstream effector of hormonal signaling, 
our results show that AAK-2 containing AMPK complexes are also upstream regulators. 
Importantly, by revealing that serotonin signaling exerts many of its effects on animal 
behavior and physiology by inactivation of AAK-2 containing AMPK complexes in the 
nervous system, our data suggest a need for reinterpretation of some of the findings in 
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which the requirement for aak-2 had only been attributed to its peripheral, metabolic 
roles.  
Results 
 
Loss of aak-2 mimics effects of elevated serotonin signaling on movement and fat 
 Given that serotonin exerted its effects on feeding in part through inactivation of 
AAK-2 containing AMPK complexes, we asked whether aak-2 mutants exhibit any other 
phenotypic consequences of elevated serotonin signaling. Consistent with the 
enhanced slowing response, aak-2 deficient animals had reduced movement rate off-
food (Figure 1A; [28]). The rate of movement of aak-2 mutant animals was similar to 
wild type animals exposed to the serotonin reuptake inhibitor, fluoxetine, and the 
already slowed off-food movement of aak-2 mutants was not further reduced by 
fluoxetine treatment (Figure 1A).  
To determine the relationship between exogenous serotonin treatment and the 
effects of endogenous serotonin increase by fluoxetine treatment, we conducted dose 
response studies. As previously reported [26], we noted that transient treatment of wild 
type animals off of food with increasing doses of exogenous 5-HT causes a progressive 
slowing of movement culminating in sickness and paralysis (Figure S1A-B). Based on 
the dose-response studies and consistent with previous similar studies [20,29,30], we 
chose the 5 mM exogenous 5-HT concentration as one that mimics the movement 
phenotypes of wild type animals treated with high doses of fluoxetine (Figure S1A). 
While both wild type and aak-2 deficient animals became paralyzed with increasing 
doses of exogenous serotonin, aak-2 mutants were more sensitive to paralyzing effects 
of high doses of serotonin, consistent with the notion that these mutants already 
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experience elevated serotonin signaling (Figure S1B). Using pharyngeal pumping rate 
as another read-out, we found that treatment of wild type animals with 5 mM 5-HT 
caused elevated feeding rate similar to fluoxetine treatment and increasing the dose of 
serotonin to 10 mM did not cause further feeding elevation (Figure S1C). The already 
elevated feeding rate of aak-2 deficient animals was unchanged with increasing doses 
of exogenous serotonin levels up 10 mM. However, as in the case of movement, aak-2 
mutants were more sensitive to deleterious effects of elevated 5-HT, such that elevating 
the dose of exogenous 5-HT beyond 10 mM had a feeding reducing effect accompanied 
by other signs of sickness (Figure S1C).  
As in mammals, enhanced serotonergic signaling in C. elegans causes fat 
reduction [19]. While in mammals, the fat reducing effects of serotonin have been 
attributed to its anorectic effects, in C. elegans serotonergic regulation of feeding 
behavior is through a cellular circuit that is distinct from serotonergic regulation of fat 
metabolism [7,19]. The fat reducing effects of elevated serotonin in C. elegans are due 
to enhancement of fat utilization in peripheral tissues. Recent studies have suggested 
that a complex regulatory loop between serotonin and octopamine signaling cascades 
in the nervous system ultimately leads to transcriptional upregulation of various 
components of fat mobilization and oxidation machineries in the periphery [19,31]. 
To determine whether loss of aak-2 mimics the effects of elevated serotonin on 
fat, we assessed fat content using the fluorescent BODIPY-labeled fatty acids and 
biochemical measurement of triacylglycerides, both of which indicated that aak-2 
mutants had reduced fat compared to wild type (Figure 1B-C). The reduced fat 
phenotype of aak-2 mutants was similar in magnitude to wild type animals subjected to 
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5 mM exogenous 5- HT and not further diminished upon 5-HT treatment (Figure 1CE; 
[19]). To verify these results, we used Coherent anti-Stokes Raman Scattering, CARS, 
a label free microscopic method for the assessment of fat levels [32–34]. The CARS 
results corroborated the noted fat reduction upon aak-2 inactivation and 5 mM serotonin 
treatment (Figure 1D-E; [19]). Moreover, the notion that aak-2 mutants have particularly 
low fat levels in their skin-like hypodermal tissues, a result readily suggested by 
treatment of these mutants with BODIPY-labeled fatty acids (Figure 1B), was 
corroborated by CARS (Figure 1E).  
Fat reducing effects of serotonin elevation are associated with increased total 
oxygen consumption [19]. Accordingly, aak-2 mutants exhibited elevated rates of 
oxygen consumption relative to wild type animals (Figure 1F). We next examined 
transcriptional expression patterns of nearly a hundred fat and sugar metabolic genes 
[35,36] by RT-PCR. Although the precise magnitude of changes were not identical and 
there were genes that were differentially regulated in aak-2 mutants and serotonin 
treated wild type animals (Figure S1D, Table S1), we noted a significant overlap 
between those that were upregulated, downregulated, or unchanged in aak-2 mutants 
and wild type animals treated with 5 mM 5-HT compared to untreated wild type animals 
(Figure S1D, Table S1). Genes that were significantly upregulated by both elevated 
serotonin and aak-2 inactivations included homologs of an acyl-CoA synthase, required 
for activation of fatty acids, a carnitine palmitoyl transferase, which can shuttle fatty 
acids across the mitochondrial membranes for fat oxidation, and a mitochondrial acyl-
CoA dehydrogenase, an enzymatic component of fat oxidation. The similarities in the 
patterns of transcriptional changes in various metabolic genes supported the notion that 
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elevated serotonin and loss of aak-2 affect fat metabolism through a common pathway. 
Finally, we examined the effects of inactivations of W01A11.5, encoding a putative 
carnitine palmitoyl transferase, cpt-1a, and F08A8.4, encoding a putative acyl-CoA 
oxidase, on fat content of aak-2 mutants. This is because we had previously shown that 
these gene inactivations partially block the fat reducing effects of elevated serotonin 
signaling [19]. These gene inactivations also partially blocked the fat reducing effects of 
aak-2 deficiency (Figure 1G-H, Figure S2A-C).  
These results combined with our previous findings suggested that loss of aak-2 
mimics the effects of elevated serotonin signaling on food intake behavior, fat, and 
movement.  
Effects of losses of aak-1 and tph-1 on aak-2 mutant phenotypes 
 As both aak-1 and aak-2 separately encode for the catalytic subunits of AMPK. 
We considered the possibility that the phenotypes caused by loss of aak-2 may in fact 
be due to aberrant activation of aak-1. However, none of the phenotypes of aak-2 
mutants were altered in aak-1; aak-2 double mutants (Figure 2A-C). Additionally, aak-1 
transcript levels were unchanged in aak-2 mutants (Figure S3). Thus, the phenotypes 
caused by loss of aak-2 were not simply compensatory responses of AAK-1 activation.  
To decipher the relationship between serotonin production and aak-2, we next 
examined tph-1; aak-2 double mutants. The feeding, fat, and movement phenotypes of 
the double mutants were either the same as those of aak-2 mutants or intermediate 
between those of tph-1 and aak-2 single mutants (Figure 2D-F). One interpretation of 
these results is that aak-2 functions, at least in part, upstream of tph-1. For instance, 
loss of aak-2 could promote production of serotonin by elevating tph-1 expression. 
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However, expression of tph-1 was unchanged in aak-2 mutants relative to wild type 
animals (Figure S3). A second interpretation is that aak-2 functions downstream of tph-1 
but only mediates some of the effects of serotonin on fat, feeding, and movement. Since 
we previously found that in the context of feeding regulation, elevated serotonin acts 
through the SER-5 receptor to cause inhibition of AAK-2 in interneurons that are not 
known to produce serotonin, we favor the second interpretation. This interpretation is 
consistent with the notion that loss of aak-2 mimics phenotypes seen when serotonin 
signaling is elevated beyond that of steady state well-fed animals.  
Reconstitution of aak-2 in the nervous system rescues the fat and movement 
defects of aak-2 mutants  
In C. elegans, aak-2 is broadly expressed in both neural and peripheral tissues 
[9,28]. To determine whether loss of aak-2 in specific tissues could account for its 
movement and fat phenotypes, we reconstituted wild type aak-2 in select tissues of the 
mutant animals. Reconstitution of aak-2 throughout the nervous system restored wild 
type movement rate (Figure 1A) and fat levels to aak2 mutants (Figure 1B) while 
reconstitutions within body wall muscle, intestine, pharyngeal muscle, and hypodermis 
failed to do so (Figure S4 and data not shown).  
We previously reported that normalized feeding rate is restored when aak-2 is 
reconstituted within only the AVJ pair of interneurons as well as the pharynx of aak-2 
mutants [7]. These transgenic animals, however, still exhibited reduced fat levels that 
were indistinguishable from those of aak-2 mutants (Figure S4). These data suggested 
that elevated serotonin signaling elicits feeding and fat phenotypes through inhibition of 
AAK-2 containing complexes in distinct regions of the nervous system.  
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Loss of aak-2 causes fat reduction independent of the dauer state  
The observations that loss of neural aak-2 mimics the effects of serotonin signaling 
forced us to re-evaluate previously published claims where requirements for aak-2 in 
various physiological processes have been largely attributed to its peripheral, metabolic 
roles. One such example is the requirement for aak-2 in fat rationing during the dauer 
stage [9]. The dauer stage of C. elegans is an altered developmental state that is 
restricted to an early larval stage [37]. Entry into the dauer state is initiated by lack of 
nutrients or excessive population density, which lead to reductions in activities of pro-
growth and developmental pathways of insulin signaling and TGF-b signaling [37]. 
Relative to non-dauer early larval animals, dauers contain elevated lipid levels, which 
presumably acts as an energetic reservoir for these non-feeding animals [37]. 
A previous study suggested that aak-2 is required for proper fat rationing during the 
dauer state [9]. Animals deficient in daf-2, encoding an insulin receptor-like gene, or in 
daf-7, encoding a neurally expressed TGF-b family ligand that links environmental 
conditions to growth and development pathways, enter the dauer state constitutively 
[38,39]. It was previously reported that daf-2; aak-2 and daf-7; aak-2 double mutants 
enter the dauer state with the expected high levels of lipids but then suffer a rapid fat 
depletion during the dauer state, implicating a specific role for AAK-2 in lipid rationing 
during the dauer stage [9]. This contrasted with our finding that the low fat phenotype of 
aak-2 deficient animals was not restricted to the dauer stage. To explore this potential 
discrepancy, we re-examined fat contents of daf-7; aak-2 and daf-2; aak-2 double 
mutants [9]. Multiple independent methods of assessing fat levels — vital staining with 
BODIPYlabeled fatty acids, fixed staining with Sudan Black B, and total lipid extraction 
followed by thin layer chromatography — all showed significant reductions in lipid levels 
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in daf-7; aak-2 and daf2; aak-2 relative to daf-7 and daf-2 mutants, respectively, both 
prior to and at the time of dauer entry (Figure 3, S5). We also examined fat levels of daf-
2; aak-2 double mutants with CARS, and consistent with all of other results, noted that 
these double mutants had low fat levels (Figure S6). Moreover, the CARS experiments 
indicated that treatment of daf-2 animals with 5 mM exogenous serotonin causes fat 
reductions to the same extent as that seen in daf-2; aak-2 mutants and exogenous 
serotonin treatment did not further reduce the fat content of these double mutants 
(Figure S6). Thus, the role of aak-2 in fat regulation is not dauer stage-specific and the 
low fat phenotype of aak-2 deficient animals is not dependent on either intact insulin or 
TGF-b pathways. 
 
aak-2 deficient animals exit dauer even in the absence of food cues 
Under normal physiological circumstances, dauers must be able to sense the 
reappearance of food to resume growth. Serotonin, an indicator of food availability, is 
known to promote dauer exit [15]. Therefore, we considered the possibility that the 
noted requirement for aak-2 in dauer survival may reflect an increased tendency of 
animals to exit the dauer stage rather than a failure to maintain dauer survival due to 
rapid exhaustion of lipid stored during this state. 
 The claim that aak-2 dauers fail to maintain survival has been based on studies 
that rely on a ‘‘dauer trap’’ system, where dauers are kept suspended within a sterile 
water drop and their survival is periodically assessed within the drop [9,11,12]. We 
noted that at the time of dauer entry nearly 100% of daf-2; aak-2 and daf-7; aak-2 
double mutants as well as daf-2 or daf-7 single mutants survived 1% SDS treatment, a 
treatment traditionally used to distinguish dauers from non-dauers [40] (data not 
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shown). Thus, at least by this criteria aak-2 deficient animals enter the dauer stage. 
After a few days in the dauer trap assay, aak-2 deficient animals exhibited features 
associated with animals that have exited dauer yet fail to grow due to lack of nutrients. 
These features included loss of radial constriction and growth of the germ-line as well 
as behaviors such as pumping that are never seen in dauers (data not shown). These 
findings suggested that rather than dying as dauers, aak-2 deficient animals appear to 
exit the dauer state but then starve to death under the conditions of the dauer trap.  
 To distinguish the possibility that aak-2 deficient animals expire as dauers or 
prematurely exit this stage, we examined daf-2; aak-2 and daf-7; aak-2 double mutants 
when maintained as dauers on plates with food (E. coli) or within the dauer trap assay 
also supplemented with food. In a timeframe coincident with previously reported loss of 
viability during the dauer state, the aak-2 deficient animals exited the dauer state and 
grew into reproductive adults (Figure 4A-B). We also rarely observed any aak-2 
deficient animals that died as dauers. These findings suggest that the reported 
requirements for aak-2 in proper dauer survival actually reflect increased tendency of 
these animals to exit this stage and are consistent with the notion that loss of aak-2 
elicits a set of phenotypes also seen upon enhanced serotonin signaling. 
 
Loss of aak-2 mimics 5-HT signaling in promoting neuroendocrine secretions 
from ASI neurons 
Serotonin is thought to promote enhanced signaling through the insulin and TGF-b 
signaling pathways in C. elegans [16]. Therefore, we asked whether inactivation of 
AAK-2 links serotonin signaling to these signaling cascades. The ciliated sensory 
neurons ASI secrete the DAF-7 TGF-b ligand as well as DAF-28, an insulin-like peptide, 
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both of which are packaged and secreted in dense-core vesicles [41,42]. To assess the 
effects of serotonin and aak-2 on dense-core vesicle secretion, we fused full-length 
DAF-28 to a fluorescent mCherry reporter and expressed the fusion in ASI neurons 
using the daf-7 promoter [43,44]. Such transgenes have been used to quantitatively 
assess dense-core vesicle mediated secretions from various C. elegans neurons 
including the ASI [41,45,46]. Secreted peptides accumulate within coelomocytes, 
scavenger cells that non-specifically endocytose molecules within the pseudocoelom. 
This reporter system has been validated by a variety of assays that have functionally 
probed the consequences of dense core vesicle secretions [45–47]. Treatment of wild 
type animals with exogenous 5-HT resulted in a ,30% increase of fluorescent signal 
accumulation in coelomocytes (Figure 5A). Similarly, loss of aak-2 increased 
accumulation of the DAF-28 reporter, which was not further enhanced by exogenous 
serotonin treatment (Figure 5A). Similar results were obtained when examining 
coelomocyte accumulation of a full length DAF-7 fused to mCherry and expressed in the 
ASI neurons (Figure S7A). 
We next set out to determine whether the enhanced coelomocyte accumulation 
of DAF-28 and DAF-7 fusion reporters in aak-2 mutants were due to increased 
transcriptional activity, enhanced secretion, or both. Transcriptional expression levels of 
daf-7 and daf-28 were indistinguishable in wild type and aak-2 mutants as assessed by 
RT-PCR assays (Figure S7B). To examine whether the enhanced accumulation of the 
reporter fusions in the coelomocytes depended on dense core vesicle secretions, we 
generated aak-2; unc31 double mutants expressing the DAF-28::mCherry transgenic 
secretion reporter. unc-31 is a neurally expressed gene that encodes for the C. elegans 
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homolog of Calcium Activated Protein for Secretion, CAPS, which is critical for fusion of 
dense core vesicles with plasma membranes [48]. Loss of unc-31 is known to block 
enhanced secretion of dense core vesicles in C. elegans [41]. Not only was the elevated 
coelomocyte accumulations of DAF28::mCherry of aak-2 mutants abrogated by loss of 
unc-31, the levels were below those seen in wild type animals and similar to the levels 
of unc-31 mutants (Figure S7C). These findings suggested that the enhanced 
secretions seen in aak-2 mutants require the canonical dense core vesicle release 
machinery.  
Within the context of feeding regulation, we previously found that 5-HT acts 
through the G protein-coupled receptor, SER-5, to ultimately cause inactivation of AAK-
2 in the AVJ pair of interneurons [7]. As ser-5 is expressed in the ASI neurons, we 
tested whether it links serotonin to enhanced secretions from these neurons. Indeed, 
loss of ser-5 abrogated enhanced accumulation of reporter fusions secreted from the 
ASI upon serotonin treatment (Figure 5B). In turn, selective reconstitution of ser-5 only 
in the ASI neurons of ser-5 mutants once again allowed for serotonin induced secretion 
from these neurons (Figure 5C). Additionally, selective ASI expression of gsa-
1(R182C), encoding a gain-of-function mutation in Gas [49], expected to mimic 
enhanced signaling through the Gas coupled SER-5 receptor [50] and causing 
inactivation of AAK-2 [7], led to increased dense-core vesicle secretion from the ASI 
neurons (Figure 5D). Finally, we showed that aak-2; ser-5 double mutants had 
increased ASI secretions similar to those seen in aak-2 mutants (Figure 5E) and that 
loss of aak-2 did not alter ser-5 gene expression (Figure S7B). 
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The epistasis and cell specific reconstitution studies presented above suggest 
that serotonin promotes enhanced secretions from the ASI neurons through activation 
of SER-5 and subsequent inactivation of AAK-2 in the ASI neurons to promote 
enhanced secretion of DAF-7 TGF-b and the DAF-28, which play critical roles in 
whether animals stay in dauer or undergo reproductive growth. 
 
Increased neuroendocrine signals contribute to dauer exit of aak-2 mutants 
Elevated secretions of TGF-b like ligand, DAF-7, and insulins, are known to 
counteract the dauer constitutive phenotypes of daf-2 and daf-7 mutants [38,39]. We 
reasoned that if enhanced DAF-7 secretion from the ASI neurons accounted, at least in 
part, for tendency of daf-2; aak-2 mutant animals to exit the dauer stage, then 
reconstitution of aak-2 in ASI neurons should promote maintenance of the dauer state. 
This was indeed the case. While daf-2 mutants stayed in dauer throughout the course of 
the experiment, by 8 days, virtually all daf-2; aak-2 had exited dauer. By contrast, after 8 
days, ,60% of transgenic animals in which aak-2 was only reconstituted in the ASI 
neurons, were still in the dauer state (Figure 6A). They retained viability as dauers since 
they remained responsive to a gentle touch (data not shown). All of these animals 
remained in the dauer state until the experiment was terminated on day 15. 
It was previously reported that loss of atgl-1, encoding a lipase required for 
mobilization of triglycerides [51], allowed dauer survival in aak-2 deficient animals by 
preventing fat loss of these mutants [9]. We therefore wondered whether the ability of 
the subset of daf-2; aak-2 deficient animals in which aak-2 was reconstituted in the ASI 
neurons could be due to restoration of fat levels. This was, however, not the case since 
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the fat levels of these animals were indistinguishable from that of daf-2; aak-2 mutants 
(Figure S4). 
Our dauer maintenance assays were done in the presence of food such that we 
could distinguish animals that exit the dauer stage from those that might expire as 
dauers. We re-assessed the role atgl-1 loss in preventing dauer exit using our assay 
conditions. Under these conditions, 100% of daf-2 or daf-7 mutants remained in the 
dauer state by day 10 post dauer entry, while nearly 100% of daf-7; aak-2 or daf-2; aak-
2 mutants had exited the dauer and resumed growth. Loss of atgl-1 delayed the rate of 
dauer exit especially during days 2–7, however, by day 10 still nearly 100% of animals 
had exited the dauer stage and resumed growth (Figure 6B). To further investigate the 
contribution of fat levels on dauer maintenance, we screened through a metabolic sub-
library of RNAi clones to identify additional genes that are important for fat reduction 
when aak-2 is lost. We identified several peroxisomal genes whose inactivation 
increased BODIPY-labeled fatty acid staining in daf-7; aak-2 animals: pmp-1, pmp-2, 
daf-22, and prx-5 (data not shown). Like atgl-1, loss of these peroxisomal genes caused 
a 2-3 day delay in the time frame of dauer exit but did not change the finding that nearly 
a 100% of animals existed the dauer stage by day 10 (data not shown). Finally, we 
examined dauer maintenance of daf-7; mgl-1; mgl-3 triple mutants. This is because 
losses of the neurally expressed metabotropic glutamate receptors encoded by mgl-1 
and mgl-3 significantly reduce fat levels of daf-7 mutants [52]. While daf-7 mutants have 
nearly 2.5 fold more lipid staining based on Sudan Black B compared daf-7; mgl-1; mgl-
3 triple mutants [52], the three triple mutants maintained dauer survival virtually similar 
to daf-7 mutants (Figure 6C). Thus, increasing lipid reserve causes a modest delay in 
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dauer exit but does not prevent it. Similarly, reduction of lipid reservoirs is insufficient to 
promote dauer exit in daf-7 mutants. 
 
Discussion 
In C. elegans, serotonin signaling modulates a series of food related behavioral, 
physiological, and metabolic responses. We previously showed that elevated serotonin 
signaling leads to an increase in feeding rate through inhibition of AAK-2 containing 
AMPK complexes in the nervous system. The data presented here demonstrate that 
inactivation of aak-2 also mimics the effects of elevated serotonin on fat reduction, 
reduced movement, and whether animals stay in dauer or undergo reproductive growth 
and development. In the context of dauer decision, our data are consistent with a model 
whereby serotonin signaling through the SER-5 receptor leads to inactivation of AAK-2 
in the ASI neurons, in turn, promoting enhanced release of the DAF-7 TGFb ligand and 
insulins from these neurons (Figure S8). 
Although reconstitution of aak-2 in only the nervous system of animals was 
sufficient to revert many of the phenotypes of aak-2 animals to nearly wild type levels, 
the requirement for aak-2 activity mapped to different regions of the nervous system for 
various phenotypes of aak-2 mutants. For instance, reconstitution of aak-2 in only the 
hlh-34 expression neurons plus the pharynx of C. elegans was sufficient to restore wild 
type feeding rates but did not alter the fat, movement, or dauer maintenance 
phenotypes of aak-2 mutants. In turn, restoration of aak-2 to the ASI neurons of C. 
elegans, the site of production of the TGF-b ligand DAF-7, was sufficient to restore 
normalized secretion of dense-core vesicles from these neurons and significantly 
restored dauer maintenance without restoration of wild type feeding, fat, or movement to 
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the aak-2 mutants. We do not yet know which subset of serotonin responsive neurons 
may specifically account for the fat and movement effects caused by loss of aak-2. The 
finding that serotonergic regulation of feeding, fat, movement, and dauer exit through 
inhibition of AAK-2 occur in different regions of the nervous system indicates that 
behavioral and physiological processes that broadly regulate energy balance, while 
coordinated by serotonin signaling, are not simply consequences of one another and 
can be differentially modulated by the nervous system. 
The recognition that loss of aak-2 mimics the effects of serotonin signaling forced 
us to re-evaluate some of the interpretations of the physiological roles attributed to AAK-
2. Specifically, it had been suggested that aak-2 deficient dauers fail to inhibit 
proliferation of their germ-lines and fail to maintain survival during this stage due to i) a 
failure in rationing of lipid reservoirs, ii) inappropriate osmotic regulation, and iii) lack of 
a hormesis-like effect caused by inappropriately high catalase activity [11]. In each of 
these cases, the dauer trap assay was used to monitor survival of dauers [9,11]. We 
found that this assay makes it difficult to distinguish between animals that exit dauer 
and succumb to early death due to factors such as starvation and animals that fail to 
maintain survival while remaining in the dauer stage. This distinction is important for 
appropriately understanding the role of aak-2 in dauer physiology. For instance, aak-2 
mutants that have been maintained in the dauer trap assay for several days exhibit 
lower fat levels, an outcome that has been interpreted as a failure by these animals to 
ration their lipid reserves during the dauer state [9,11]. However, lower lipid levels would 
also be expected if aak-2 deficient dauers exit this stage and resume growth but then 
starve due to lack of nutrient availability in the dauer trap assay. To differentiate early 
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dauer exit from death during the dauer state, we added E. coli to the dauer trap assay 
or kept the aak-2 dauers on plates with food. Under these circumstances, we did not 
see aak-2 mutants that expired as dauers. Rather, we found that virtually all aak-2 
deficient dauers exited this state and resumed normal patterns of growth. Moreover, we 
found that elevation of serotonin signaling or loss of aak-2 promoted enhanced release 
of the DAF-7 TGF-b and the DAF-28 insulin, systemic regulators of animal growth and 
development. Thus, our data suggest that the noted effects of loss of aak-2 on dauer 
survival are due its requirement for preventing early dauer exit. Our results, however, 
neither rule out a role for AAK-2 in modulating metabolism in the periphery including 
during periods of nutrient deprivation, nor challenge the notion that AAK-2 may regulate 
the activity of ATGL-1. In fact, a recent study indicated that fat reduction induced by 
elevated serotonin signaling in the nervous system, a condition that we suggest is 
mimicked by loss of aak-2 from the nervous system, depends on transcriptional 
upregulation of atgl-1 in the periphery [31]. 
Our analyses of fat staining in aak-2 mutants led to different conclusions than 
those previously reported for these mutants [9]. These discrepant results highlight some 
of the methodological challenges in assessing C. elegans fat levels. Fixed staining and 
biochemical methods were previously used to claim that aak-2 mutants enter dauer with 
wild type levels of fat [9]. Using the same methodologies, we instead found that aak-2 
mutants have lower levels of fat at all stages including at the time of dauer entry. The 
results of our fixed dye and biochemical fat measurements were corroborated by vital 
BODIPY-fatty acid labeling as well as label free CARS. Although fixed staining methods 
and biochemical methods have in the past few years been touted as the strategies by 
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which C. elegans fat should be assessed [53,54], in our experience both methods are 
prone to an enormous amount of variability and can be fairly insensitive when used to 
gauge total lipid contents of whole animals. Fixed staining methods rely on 
permeabilization of the cuticle to allow penetrance of dyes, a process that can be 
difficult to achieve uniformly. The fixed staining methods also rely on alcohol 
dehydration steps, which if not done properly can dissolve away triglycerides. Similarly, 
the biochemical measurements of extracted triglycerides are prone to a great deal of 
experimental variation since they rely on relatively large populations of animals and 
extraction procedures that can have vastly different efficiencies in different trials. Thus, 
while each of these methods can provide valid assessments of fat levels, it is important 
to recognize their limitations and susceptibility to a high level of operator error that can 
lead to reporting of erroneously high or low levels of C. elegans fat content. 
In C. elegans, as in mammals, activation of AMPK causes fat reduction [55]. 
Thus, it may seem paradoxical that loss of aak-2 could also result in fat reduction. In 
analogy to mammalian systems, energy deprivation is expected to lead to AMPK 
activation in C. elegans and subsequent mobilization of fat reservoirs as an energy 
generating strategy. In mammals, the fat reducing effects of AMPK are largely 
attributable to activation of this kinase complex in peripheral tissues [56]. While it has 
not been formally shown to be the case in C. elegans, we speculate that the noted fat 
reductions caused by activation of AMPK are similarly dependent on activity of this 
kinase complex in peripheral tissues. By contrast, our findings indicate that the reduced 
fat of aak-2 mutants is due to loss of AAK-2 activity from the nervous system. As in the 
case of elevated serotonin signaling, inactivation of neural AAK-2 is expected to occur 
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under conditions of plentiful food supplies. In mammals, actions of hormonal cues of 
food availability on the nervous system are similarly associated with enhanced rates of 
fat oxidation [57]. For example, increased T3 thyroid hormone, in cases of 
hyperthyroidism, inactivates hypothalamic AMPK leading to increased brown adipose 
tissue thermogenesis and weight loss without inducing changes in food intake [58]. 
Additionally, it has been suggested that hypothalamic inhibition of AMPK may stimulate 
the sympathetic nervous system that innervates peripheral tissues leading to activation 
of AMPK in these tissues and stimulation of peripheral fatty acid oxidation [58,59]. 
Finally, enhanced serotonin signaling in mammals also promotes enhanced fat 
oxidation, although it is unknown whether this enhancement is dependent on neural 
AMPK inhibition [60–63]. Thus, in both C. elegans and mammals, inhibition of neural 
AMPK is associated with enhanced peripheral fat oxidation. An area of divergence 
between C. elegans and mammals are the effects of elevated serotonin signaling or 
inactivation of hypothalamic AMPK on feeding behavior. While elevation of serotonin 
signaling causes feeding increase through inhibition of AAK-2 in specific neurons of C. 
elegans, elevated serotonin signaling or inhibition of hypothalamic AMPK are thought to 
cause satiety in mammals [3,57,59]. 
There is ample evidence to assume that rather than simply a binary on/off 
indicator of food availability, serotonin-signaling functions along a continuum of levels. 
The available data support the existence of at least three states: a level of serotonin 
signaling seen in well-fed animals, which is lowered as animals are removed from food, 
and a highly elevated level that drives transient behaviors such as the enhanced 
slowing response. One appealing aspect of the regulatory link between serotonin 
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signaling and AAK-2 containing AMPK complexes is that the known features of AMPK 
regulation could also account for a variety of regulatory states. For instance, AMPK can 
be in an activated state during periods of nutrient deprivation, in an intermediate state (a 
nonactivated, non-inhibited state) during a well-fed state, or in a fully inhibited state as 
that mimicked by loss of aak-2 or elevation of serotonin levels beyond those of well-fed 
animals. Under standard laboratory conditions, the behavioral phenotypes of aak-2 
mutants, highly elevated feeding rate and dramatically reduced movement rate, are 
seen transiently when food deprived wild type animals reencounter food. Therefore, we 
speculate that the burst of serotonin signaling upon re-encountering food leads to 
inhibition of neural AAK-2 containing complexes and subsequent behavioral and 
physiological outcomes seen under these conditions. As serotonin levels return to the 
level of well-fed animals, neural AAK-2 complexes are likely to be in an intermediate 
state, neither activated nor fully inhibited. 
In numerous organisms, AMPK has been extensively studied as a master 
regulator of energy balance. In most of these cases, AMPK is considered to function in 
the context of peripheral tissues and as a downstream effector of hormonal signals 
[1,2]. Our findings here demonstrate that the AAK-2 containing AMPK complexes can 
also act as an upstream regulator of hormonal pathways by modulating their neural 
secretions. The molecular mechanisms that promote enhanced DCV secretions from 
the ASI neurons upon AAK-2 inactivation remain to be identified. Whether promotion of 
DCV secretion is a general feature of AAK-2 inhibition or if it is dependent on particular 
neural contexts also remains to be seen. 
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Materials and Methods 
 
Strains 
Standard C. elegans methods were used for strain construction [64]. N2 Bristol was 
used as the wild type control and the following mutant alleles were analyzed: ser-
5(tm2654)I, aak-1(tm1944)III, tph1(mg280)III, daf-2(e1370)III, daf-7(e1372)III, unc-
31(ft1)IV, aak-2 (ok524)X, tph-1(mg280)III; aak-2(ok524), aak-1(tm1944); aak2(ok524), 
daf-2(e1370)III; aak-2(ok524), daf-7(e1372)III; aak2(ok524), unc-31(ft1)IV; aak-
2(ok524). Transgenic animals were generated by injecting plasmids and the unc-
122::gfp or myo-3::gfp co-injection marker at a concentration of 50 ng/ml. For secretion 
assays, animals carrying full length DAF-28::mCherry and DAF7::mCherry driven by a 
daf-7 promoter were used. Previously described [41] wild type animals carrying 
integrated copies of these transgenes were crossed into indicated mutant backgrounds 
to allow for direct comparisons. Dauer constitutive strains were maintained at 15uC, 
except when testing dauer entry and maintenance, which were conducted at 25uC. 
 
Plasmid construction  
Plasmids were constructed using Gateway Technology. pmyo-2 and pmyo-3 entry 
vectors were constructed as described [47]. punc119::aak-2a, punc-119::aak-2c, pgrl-
21::aak-2a, pgrl-21::aak-2c, pdaf7::aak-2a, pdaf-7::aak-2c were generated by Gateway 
cloning. For the unc-119 promoter, 2000 bp including the ATG was amplified by PCR 
from genomic DNA and sub-cloned into Gateway entry vector pDONR-P4-P1R. For the 
daf-7 promoter, 2800 bp including the ATG was amplified by PCR from genomic DNA 
and sub-cloned into Gateway entry vector pDONR-P4-P1R. For the grl-21 promoter, 
745 bp including the ATG was amplified by PCR from genomic DNA and sub-cloned 
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into Gateway entry vector pDONR-P4-P1R. Rescue constructs were generated using 
the pKA453 plasmid to obtain promoter::orf::intercistronic::GFP polycistronic fusions. 
This resulted in the expression of GFP from the same transcript as the ORF without 
modification. pdaf-7::daf-7::mCherry and pdaf-7::daf-28::mCherry, integrated lines were 
generated as described in [41]. To generate pdaf-7::ser-5::gfp, and pdaf7::gsa-
1(R182C)::gfp, ser-5 or gsa-1 cDNA, was amplified and cloned according to the 
procedure outlined in [7], and recombined using Gateway cloning methodology. The 
R182C mutation was inserted into the gsa-1 sequence by oligo-mediated sitedirected 
mutagenesis and the desired mutation was confirmed by sequencing the resulting 
plasmid. 
 
Lipid analysis 
Extended methods for BODIPY staining, triglyceride measurements, and Sudan 
Black B staining are provided in reference [65]. Sudan Black B assays were performed 
at room temperature (22uC) [38] with the following modification to minimize staining 
variability, which allowed for quantitative comparisons between various genotypes: 
animals from one genotype were labeled with fluorescein isothiocyanate (FITC) and 
then fixed and stained in the same tube as unlabeled animals from another genotype. 
For quantitation, Sudan Black images were collected on a Zeiss Axioplan 2 microscope 
fitted with a Hamamatsu ORCA-AG camera. Staining intensities were quantitated using 
Improvision Openlab software. Mean pixel intensity was calculated for staining in the 
region from the first intestinal cells adjacent to the pharynx midway through the animal 
to the vulva. Background was determined based on pixel intensity of nonspecific 
staining in the pharynx. Values are reported as mean pixel intensity minus background 
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for at least ten randomly selected animals per genotype. In each case, test and control 
animals were fixed and stained in the same tube. 
Biochemical determination of extracted triglycerides: synchronized nematodes 
from a liquid culture of approximately 5000 animals were washed three times by 
centrifugation and resuspension in 10 ml S-basal medium supplemented with 0.1% 
PEG8000. After the washes, the nematode population pellet was finally suspended in 
approximately 200 ml of S-basal +0.1% PEG-8000. 50 ml of this suspension was 
reserved for protein determination (see below) and 100 ml of suspension was diluted 
with 59 ml of water for lipid determination. To extract triglycerides, chloroform (0.2 ml) 
and methanol (0.4 ml) was added to the 0.159 ml aqueous suspension of nematodes 
and mixed by periodic vigorous vortexing over 20 min. An additional 0.2 ml of 
chloroform and 0.2 ml of 0.2 N HCl were then added. The mixture was mixed by 
vigorous vortexing over 20 min, then centrifuged at 2,500 g for 5 min to separate the 
phases. The lower phase was washed once with 0.75 ml of the aqueous phase derived 
from a mixture of chloroform, methanol, 0.1 N HCl (1:1:1), then concentrated by vacuum 
centrifugation. The residue was dissolved in 25 ml of chloroform:methanol (1:1), 10 ml 
of which was applied to a thin layer chromatography plate (Merck silica gel-60), along 
with triglyceride standards (0.5–10 mg). The samples and standards were eluted using 
a hexanes-ether-acetic acid mixture (70:30:1) and the plate was developed by spraying 
with phosphomolybdic acid stain (Sigma) and heating in a 125uC oven for 10 min. An 
image of the plate was acquired using a flat bed scanner (Epson) and the integrated 
density of the bands that exhibited the same elution profile as the triglyceride standards 
was quantified. The optical densities were then converted to TAG mass by comparison 
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to a TAG standard curve. The mass of lipids obtained from each extraction was 
normalized to the total protein extractable for 3-4 independent nematode cultures per 
experimental condition. To determine total protein levels for normalization, 250 ml of 
extraction buffer (7 M urea, 2 M thiourea, 4% CHAPS, 50 mM tris-HCl pH 7.4, 5 mM 
TCEP, 1 mM EDTA) was added to the 50 ml suspension of nematodes from the same 
suspension that was used for TAG extraction. The sample was rotated end-over-end 
and periodically vortexed for 1 hr at 37uC. The sample was centrifuged (10 min at 
16,500 g) and the amount of protein in the supernatant was determined by Bradford 
assay (Bio-Rad). 
For BODIPY staining a 1 mg/ml stock of C1-BODIPY 500/ 512 C12 (Invitrogen) 
was added to NGM plates seeded with OP50 at a final dilution of 1:50,000. 
Synchronized L1 animals were added to plates and imaged as Day-1 adults after 
growth at 20uC. Fluorescent images were acquired on a Zeiss Axioplan II microscope 
outfitted with a digital CCD camera using the same sub-saturating exposure settings. 
Using ImageJ, the area surrounding the head of the animal (starting just above the 
intestinal cells) was selected from which total integrated intensity was derived. At least 
10 animals were imaged for each treatment and experiments were repeated a minimum 
of 2 times. Significance was determined using a student’s t-test. 
For the coherent anti-stokes Raman scattering, CARS, imaging [32], a 
picosecond optical parametric oscillator (picoEmerald - APE) with the stokes tuned at 
1064 nm and pump at 817 nm in order to match the lipid CH2 stretching mode at 2845 
cm21 [33,34] was used. Both laser pulses are synchronized in time and space and 
directed to a galvanometric mirror imaging microscope (Nikon Ti-U inverted microscope 
 28 
coupled to a TriM Scope II - LaVision BioTec system) and focused onto the sample by a 
60X Nikon objective. The backscattered signal is then directed to a set of dichroic and 
band pass filters in order to remove the pump and stokes lasers and to detect only the 
anti-stokes signal in a photomultiplier (Hamamatsu H7422-40). To quantitate the CARS 
signal for each animal, all of the Z-slices were combined, and background and maximal 
values were calculated from these combined slices. Regions of interest (head 
hypodermal region or intestinal areas) were selected and quantitated for each animal 
and integrated intensity densities are reported for each region. For each genotype 
and/or serotonin treatment, average data from at least five separate animals are 
reported. 
Dauer entry and dauer exit 
To assess dauer entry, we used 1% SDS treatment as previously describe [40]. 
Post treatment, animals were gently tapped to monitor movement to determine viability. 
At least 70 animals per conditions were tested. For dauer exit, 100 animals were plated 
on each of 5 plates—seeded with OP50 (or HT115 in the case of RNAi bacteria) and 
rimmed with 40% glycerol—and incubated at the restrictive temperature (25uC). After 
48 h, virtually all daf-c animals were in dauer. Plates were kept at 25uC and once per 
day, animals that had exited dauer were picked off the plates and counted. Graphed 
data reflects the averages of 5 plates of 100 animals. 
 
Movement 
Well-fed, synchronized young adult animals were washed twice with S-basal and 
plated on unseeded NGM plates. Movement was assayed 5 min after plating by 
counting the number of body bends per 20 s. Ten animals were counted per strain. 
 29 
 
Secretion 
Strains were synchronized by hypochlorite treatment and the synchronized L1s 
were plated onto 6 cm NGM plates seeded with OP50. Animals were grown at 20 uC for 
2 days until they reached L4 stage. Sub-saturating fluorescence images of the first pair 
of coelomocytes from 20–30 transgenic animals were recorded at 166magnification 
using a Zeiss Axioplan 2 microscope fitted with a Hamamatsu Orca II camera. 
Fluorescence intensities were quantified using ImageJ software. The outline of each 
coelomocyte was traced using the image from the punc-122::GFP coelomocyte marker. 
The fluorescence of DAF-28::mCherry or DAF7::mCherry within that area was then 
measured. The mean fluorescence for each cell was subtracted from the minimum 
fluorescence (background) within that cell. Fluorescence intensities were normalized to 
the wild type, sham treated control. 
 
RNAi  
HT115 bacteria containing each RNAi vector were tested as previously 
described. Briefly, bacteria were grown overnight. The following day, bacteria were 
pelleted and resuspended to 2x concentration prior to plating on NGM agar containing 6 
mM IPTG and 25 mg/ml ampicillin. Animals were added to plates (BODIPY staining) or 
liquid cultures (TLC) as L1s and grown until the L4 stage. Animals were imaged as L4 
(BODIPY) or subjected to total lipid extraction followed by thin layer chromatography 
(TLC). 
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Oxygen consumption  
Oxygen consumption was measured in synchronized L4 animals that were 
washed twice with S-basal. Per genotype, 200 animals were placed in a plate with 
biosensor film used to gauge oxygen consumption (BD Biosciences, Cat# 353830). We 
previously determined that a three-hour period allows for biosensor film to reach 
equilibrium. The data are end-point measurements, which reflect oxygen consumption 
rather than biosensor equilibrium. Per genotype, the measurements were done in 
quadruplicate, and each experiment repeated 3 times. Measurement of fluorescence 
was by a Molecular Devices FlexStation. 
 
 
Statistical analysis  
For pair-wise comparisons, student’s t-test was used. For multiple comparisons, 
one-way ANOVA with Bonferroni correction was used. Error bars represent +/-SEM. 
*represents statistical difference relative to wild type unless otherwise indicated. P-
values are indicated in figure legends. 
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 Figure 1.1 Loss of aak-2 mimics increase serotonin signaling 
A. aak-2 mutants and wild type animals (WT) treated with exogenous serotonin (5 mM) 
or fluoxetine (50 µg/mL) have fewer body bends when removed from food. Pan-
neuronal reconstitution of aak-2 (punc-119) restores wild type body bends to aak-2 
mutants. n=10, *p<0.05, one-way ANOVA with Bonferroni correction for multiple 
comparisons. B. aak-2 deficient animals have reduced hypodermal BODIPY 
fluorescence relative to WT. Wild type BODIPY staining is restored to aak-2 mutants 
when aak-2 is reconstituted in the nervous system (punc-119). n=10, ***p<0.001, one-
way ANOVA with Bonferroni correction for multiple comparisons. C. Wild type animals 
treated with 5mM 5-HT have significantly lower triglycerides per protein (TAG/protein) 
compared to sham treatment as determined by total lipid extraction followed by Thin 
Layer Chromatography. Sham treated aak-2 mutants already have significantly lower 
TAG/protein compared to WT and 5mM 5-HT treatment does not result in further 
reduction. TAG/protein levels of 5-HT treated WT are not significantly different than 
those of aak-2 +/- 5-HT. n=3, *p<0.05, Student’s t-test. D-E. Quantitation of signal 
intensities of Coherent anti-Stokes Raman Scattering, CARS, of WT and aak-2 mutants 
+/- 5mM 5-HT treatment. 5-HT treatment lowered the CARS signal intensities from the 
intestinal (D) and head hypodermal (E) regions of WT animals. aak-2 mutants had lower 
signal intensities relative to WT, which was not further reduced by 5 mM 5-HT 
treatment. Signal intensities of 5-HT treated WT were not significantly different than 
those of aak-2 +/- 5-HT. n=5, *p<0.01, Student’s t-test. F. Loss of aak-2 or 5mM 5-HT 
treatment caused elevated oxygen consumption. WT and aak-2 mutants (n=800 per 
genotype) were sham treated. Data are expressed as a percentage of WT. Error bars 
represented +/- SEM. **p < 0.01 versus sham treated WT, one-way ANOVA with 
Bonferroni correction for multiple comparisons G-H. Loss of cpt-1a via RNAi restores 
wild type BODIPY staining to hypodermis (white arrow) and intestine (yellow arrow) of 
aak-2 mutants. Representative BODIPY staining images (G) and corresponding 
quantitations (H) are shown. n=5, *p<0.05, Student’s t-test.  
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Figure 2. Effects of losses of aak-1 and tph-1 on aak-2 mutant phenotypes 
A-C. Phenotypes of aak-2 loss of function are not dependent on aak-1. Feeding (A), 
movement (B), and hypodermal BODIPY staining levels (C) of aak-1; aak-2 double 
mutants are not significantly different than those of aak-2 mutants. For feeding, movement 
and BODIPY measurements, n=10, *p<0.05, Student’s t-test. Error bars represent +/-
SEM. D-F. Loss of aak-2 elicits feeding (D), movement (E), and fat phenotypes (F) even 
in serotonin deficient tph-1 mutants. The feeding rate of tph-1; aak-2 mutants was 
significantly different than both tph-1 and aak-2 single mutants (D). tph-1; aak-2 double 
mutants moved significantly more slowly than tph-1 or WT but statistically 
indistinguishable than aak-2 mutants off of food (E) For BODIPY staining in the 
hypodermal head region, loss aak-2 further reduced the already low hypodermal head 
staining of tph-1 mutants (F). For feeding, movement and BODIPY measurements, n=10, 
*p<0.05, Student’s t-test. Error bars represent +/-SEM. Please note that the BODIPY 
quantitations are of the head hypodermal region only. While tph-1 mutants have been 
reported to have elevated intestinal fat levels, their head hypodermal region actually has 
less staining relative to WT animals. To be consistent with our various other BODIPY 
measurements, we have concentrated on the same head hypodermal region when 
comparing tph-1 with tph-1; aak-2.  
 35 
 
 36 
Figure 3. daf-7; aak-2 and daf-2; aak-2 have reduced fat relative to daf-7 and daf-2 
at all stages of development. A. daf-7; aak-2 dauers have significantly reduced BODIPY 
fluorescence relative to daf-7 on the first day after the dauer molt. Insets show entire 
animals and the bottom panel shows a zoomed-in selection, denoted by the yellow box, 
from the top panel. B. Quantification of anterior hypodermal BODIPY fluorescence for 
daf-7 and daf-7; aak-2 animals on the first day after the dauer molt. n=8. * p<0.05, 
Student’s t-test. C. Representative Sudan Black B staining of daf-7 (top) or daf-7; aak-2 
(bottom) animals on the first day after the dauer molt. D. Representative Sudan Black B 
staining of daf-2 (top) or daf-2; aak-2 (bottom) animals on the first day after the dauer 
molt. E. daf-7; aak-2 animals have significantly lower TAG/protein than daf-7 animals kept 
at the restrictive temperature (25 °C) on the first day after the dauer molt as determined 
by total lipid extraction followed by Thin Layer Chromatography. n=4, * p< 0.05, Student’s 
t-test. F. daf-2; aak-2 animals have significantly lower TAG/protein than daf-2 animals 
kept at the restrictive temperature (25 °C) on the first day after the dauer molt as 
determined by total lipid extraction followed by Thin Layer Chromatography. n=4, * p< 
0.05, Student’s t-test. G. L4 stage daf-7; aak-2 animals have significantly reduced 
BODIPY fluorescence intensity relative to daf-7 animals. Insets show the anterior portion 
of the animal and the bottom panel shows a zoomed-in selection from the top panel. H. 
Quantification of anterior hypodermal BODIPY fluorescence for daf-7 and daf-7; aak-2 
animals as L4 animals. n=10, * p<0.05, Student’s t-test. Error bars represent +/-SEM. 
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Figure 1.4. aak-2 deficiency causes dauer exit. A-B. 100% daf-2; aak-2 (A) and daf-7; 
aak-2 (B) animals exit dauer when kept on plates with food (E. coli OP50) at the restrictive 
temperature (25 °C) and resume reproductive, while 100% daf-2 (A) and daf-7(B) mutants 
animals maintain dauer under similar conditions. A representative comparison is shown. 
Similar rates of exit and growth were found in at least 5 independent experiments per 
comparison. 
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Figure 1.5. Elevated serotonin or loss of aak-2 cause increased dense-core vesicle 
secretion from ASI neurons. A-B. Quantitation of tagged DAF-28::mCherry (A) and 
DAF-7::mCherry (B) accumulation in coelomocytes. daf-28::mCherry and daf-7::mCherry 
were expressed in the ASI neurons using a daf-7 promoter. Error bars represent standard 
error. * p < 0.05 relative to WT, Student’s t-test C. Quantitation of tagged DAF-
28::mCherry accumulation in coelomocytes when ser-5 is reconstituted in ASI (pdaf-7) in 
otherwise ser-5 deficient animals. * p < 0.05 relative to WT, Student’s t-test. D. Secretion 
of DAF-28::mCherry from the ASI neurons is elevated upon ASI specific expression of 
gsa-1(R182C), encoding a gain-of-function version of Gαs, previously shown to cause 
inactivation of AAK-2. Error bars represent standard error. * p < 0.05, Student’s t-test, 
relative to WT E. Elevated secretion of DAF-28::mCherry form ASI in aak-2 mutants is 
not dependent on ser-5. Error bars represent standard error. * p < .05 relative to WT, 
Student’s t-test. In A-E, punc-122::GFP was used to mark coelomocytes. Each bar 
represents examination of 20–30 transgenic animals. For each comparison, the 
transgene of interest was introduced into indicated backgrounds by crossing. 
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Figure 1.6. Reconstitution of aak-2 in ASI partially rescues dauer exit. A. daf-2; aak-
2 animals exit dauer when kept on plates at the restrictive temperature (25 °C), while daf-
2 animals maintain dauer. Reconstitution of aak-2 in only the ASI neurons restores dauer 
maintenance to ~60% of daf-2; aak-2 double mutants. Non-transgenic siblings do not 
show any improved dauer maintenance. Animals exiting dauers grew to adulthood in each 
case. We did not examine these dauers beyond day 15 only because it became 
increasingly difficult to maintain these plates contamination free and prevent the dauers 
from escaping the plates. B-C. RNAi-mediate knockdown of atgl-1 delays dauer exit for 
daf-2; aak-2 (B) and daf-7; aak-2 (C) animals but does not allow for dauer maintenance 
beyond the time that a 100% of vector treated animals have exited the stage and resumed 
growth. While relative to daf-7 mutants, daf-7; mgl-1; mgl-3 triple mutants have low fat 
levels, they maintain dauer as well as daf-7 mutants (C). Each of the graphed data in A-
C reflects the averages of 5 plates of 100 animals per genotype. A representative result 
is shown. The indicated results were repeated in at least three independent trials. 
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Figure 1.S1, related to Figure 1.1 Feeding and movement responses of WT and aak-2 
mutants to increasing doses of exogenous 5-HT. A. Treatment of wild type animals with 
increasing doses of exogenous 5-HT causes a progressive reduction in movement and 
ultimately paralysis. The movement rates of animals treated with 5mM 5-HT were similar 
to those treated with high concentrations of fluoxetine, suggesting that this dose of 
exogenous 5-HT mimics the effects of elevating endogenously produced 5-HT. Well-fed 
animals were washed twice with S-Basal and transferred to assay plates without a 
bacterial lawn. Locomotion rate was recorded after 5 minutes for a minimum of 10 animals 
of each genotype per concentration. B. Relative to wild type animals, aak-2 mutants are 
more sensitive to paralysis caused by escalating doses of 5-HT. At least 30 animals of 
each genotype per concentration were tested. Movement was scored after a 5-minute 
exposure to 5-HT. C. Effects of various doses of 5-HT on feeding. Treatment of WT 
animals with increasing doses of 5-HT caused a progressive elevation of pumping rate 
that reached its maximal levels at 5mM and was not further increased at 10 or 20 mM 
concentrations of exogenous 5-HT. The already elevated feeding rates of aak-2 mutants 
were not further increased by up to 10mM exogenous 5-HT treatment. Consistent with 
the enhanced susceptibility of aak-2 mutants to deleterious effects of high exogenous 5-
HT, aak-2 mutants became sickly and displayed lower than wild type feeding at 20mM 
concentration of 5-HT. D. 5mM 5-HT treated wild type animals and untreated aak-2 
animals show significant overlap in transcription expression of indicated metabolic genes 
relative to untreated wild type animals. Transcript levels of nearly 100 fat and sugar 
metabolic genes were determined by real-time PCR (RT-PCR). List of the genes and their 
predicted functions are provided in Table S1. Genes found to be upregulated or 
downregulated in 5-HT treated wild type animals or in untreated aak-2 animals were 
validated using cDNA preparations from two independent nematode growths. Error Bars 
represent +/-SEM.  
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Figure 1.S2, related to Figure 1.1 A. RNAi inactivation of cpt-1a (W01A11.5) restored 
normalized triglycerides (TAG) per protein (TAG/protein) measurement. WT and aak-2 
mutants were grown either on vector RNAi control or on W01A11.5 RNAi. n=3, *p<0.05, 
Student’s t-test. Error bars represent +/-SEM. B. Loss of F08A8.4, encoding a putative 
acyl-CoA oxidase, via RNAi restores BODIPY staining to aak-2 mutants. Representative 
images of BODIPY staining. C. Quantitation of hypodermal BODIPY fluorescence 
intensity shown in B. n=5, *p<0.05, one-way ANOVA with Bonferroni correction for 
multiple comparisons.  
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Figure 1.S3, related to Figure 1.1. Transcript levels of tph-1 and aak-1 are unchanged 
in aak-2 mutants relative to WT as assessed by RT-PCR assay. In each case, data are 
normalized to average of the WT levels. n=3, error bars represent +/-SEM  
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Figure 1.S4, related to Figure 1.1 Quantitation of BODIPY fluorescence intensity shows 
that reconstitution of aak-2 in various peripheral tissues or in neurons implicated in 
feeding or dauer exit does not rescue the low fat of aak-2 mutants. Data for reconstitution 
in the body wall muscle (pmyo-3::aak-2), hypodermis (pgrl-21::aak-2), hlh-34 neurons, 
likely AVJ, implicated in feeding elevation upon AAK-2 inactivation (phlh-34::aak-2), ASI 
neurons (pdaf-7::aak-2) are shown. n=10, *p<0.05, one-way ANOVA with Bonferroni 
correction for multiple comparisons. Asterisks indicate significance relative to WT. 
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Figure 1.S5, related to Figure 1.2 aak-2 deficient dauer animals have reduced fat at all 
stages. A-D. Sudan Black B staining of three representative daf-7 (A,C) and daf-7; aak-2 
(B,D) animals on day 1 (A,B) and day 4 (C,D) of dauer. E-H. Representative BODIPY-
labeled fatty acid staining of daf-7 (E,G) and daf-7; aak-2 (F,H) as L2 larvae (E,F) and L4 
larvae (G,H). I-J. Representative images of BODIPY-labeled fatty acid stained daf-2 (I) 
and daf-2; aak-2 (J) L4 larvae. K-N. Sudan Black B staining of representative daf-2 (K, 
M) and daf-7; aak-2 (L,N) animals on day 1 (K,L) and day 4 (M,N) of dauer.  
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Figure 1.S6, related to Figure 1.2. daf-2; aak-2 animals have reduced fat relative to daf-
2 animals. Quantitation of signal intensities of coherent anti-Stokes Raman Scattering, 
CARS, imaging of daf-2 and daf-2; aak-2 as L4 animals +/- 5mM 5-HT treatment. 5-HT 
treatment lowered the CARS signal intensities from head hypodermal regions of daf-2 
animals. daf-2; aak-2 mutants had lower signal intensities relative to daf-2, which was not 
further reduced by 5 mM 5-HT treatment. Signal intensities of 5-HT treated daf-2 were 
not significantly different than those of aak-2 +/- 5-HT. n=5, *p<0.05, Student’s t-test. 
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Figure 1.S7, related to Figure 1.4 A. As in DAF-28::mCherry (Figure 4), treatment with 
5mM 5-HT or loss of aak-2 promote enhanced secretions of DAF-7::mCherry expressed 
in the ASI neurons using a daf-7 promoter, as assessed by the coelomocyte accumulation 
assay. punc-122::GFP was used to mark coelomocytes. The daf-7::mCherry transgene 
was introduced into indicated backgrounds by crossing. WT and aak-2 mutants were 
sham treated. Data are shown relative to sham treated WT animals. Each bar represents 
examination of 20–30 transgenic animals. Error bars represent standard error. *p <0.05, 
one-way ANOVA with Bonferroni correction for multiple comparisons. B. Loss of aak-2 
does not significantly alter gene expressions of daf-7, daf-28, or ser-5 as measured by 
RT-PCR. In each case, data are normalized to average of the WT levels. n=3, error bars 
represent +/-SEM C. Loss of unc-31 abrogates the elevated coelomocyte accumulation 
of DAF-28::mCherry seen upon 5mM 5-HT treatment or loss of aak-2. Error bars 
represent standard error. Asterisks denotes significance relative to sham treated WT 
animals, *p<0.05, one-way ANOVA with Bonferroni correction for multiple comparisons. 
An average of 20-30 transgenic animals were examined for each bar. The daf-28 
neuropeptide was tagged with mCherry, while punc-122::GFP was used to mark 
coelomocytes. 
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Figure 1.S8 Model Inactivation of AAK-2 in the hlh-34 expressing AVJ neurons mediate 
the effects of elevated serotonin signaling on feeding while inactivation of AAK-2 in the 
ASI neurons mediates the effects of elevated serotonin signaling in enhanced release of 
the DAF-7 TGF-β ligand and the DAF-28 insulin. In both cases, serotonin signaling 
through the SER-5 receptor leads to activation of Protein Kinase A, which in turn, causes  
inhibition of AAK-2. 
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Table 1.S1 Effects of 5mM 5HT and aak-2 loss on expression of select metabolic 
genes. Effects of 5mM 5-HT and aak-2 loss on expression of select metabolic genes. 
Predicted annotations for each of the genes are indicated. RT-PCR assays were 
repeated at least twice for genes whose transcription was altered by addition of 5mM 
5-HT or loss of aak-2. Data are normalized to untreated WT for each gene. 
 
Gene ID Putative Function WT + 5mM 5HT aak-2 
FAT METABOLISM 
F46E10.1 Acyl-CoA Synthetase 1.18 0.93 ± 0.35 
T01B8.6 Acyl-CoA Synthetase 4.64 ± 2.94 1.80 ± 0.64 
Y65B4BL.5 Acyl-CoA Synthetase 0.59 0.88 ± 0.06 
Y76A2B.3 Acyl-CoA Synthetase 0.81 0.68 ± 0.10 
F38H4.8 Enoyl-CoA Hydratase 0.70 ± 0.30 0.38 ± 0.15 
F43H9.1 Enoyl-CoA Hydratase 1.12 0.71 ± 0.11 
R06F6.9 Enoyl-CoA Hydratase 0.92 0.85 ± 0.06 
F56B3.5 Enoyl-CoA Hydratase 1.48 0.93 ± 0.25 
T05G5.6 Enoyl-CoA Hydratase 1.20 1.64 ± 0.38 
Y105E8A.4 Enoyl-CoA Hydratase 0.76 0.87 ± 0.061 
F09E10.3 Short-chain Dehydrogenase 1.05 0.71 ± 0.14 
K05F1.3 Acyl-CoA Dehydrogenase 2.63 1.26 ± 0.77 
F01G4.2 3OH-Acyl CoA Dehydrogenase 0.89 1.01 ± 0.02 
B0272.3 3OH-Acyl CoA Dehydrogenase 1.7600 ± 1.24 1.71 ± 0.79 
F08A8.2 Acyl-CoA Oxidase-1 1.06 1.77 ± 0.33 
F08A8.3 Acyl-CoA Oxidase 0.49 1.05 ± 0.49 
F08A8.4 Acyl-CoA Oxidase 0.46 0.38 ± 0.24 
F25C8.1 Acyl-CoA Oxidase-1 0.83 0.71 ±0.08 
F59F4.1 Acyl-CoA Oxidase-1 0.93 ± 0.20 0.96 ±0.46 
T02G5.4 Acetyl-CoA Thiolase 0.92 1.11 ± 0.01 
B0303.3 KetoAcyl-CoA Thiolase 1.50 1.22 ± 0.02 
W08D2.4 Fat-3  ∆6 Desaturase 0.98 0.87 ± 0.10 
T13F2.1 Fat-4  ∆5 Desaturase 1.33 1.37 ± 0.03 
Y67H2A.8 Fat-1  ∆3 Desaturase 1.22 1.11 ± 0.12 
W02A2.1 Fat-2  ∆12 Desaturase 1.07 0.64 ± 0.39 
VZK822L.1 Fat-6 1.07 0.93 ± 0.18 
ZK742.5 lbp-6 0.69 ± 0.51 0.83 ± 0.29 
T22G5.2 lbp-7 1.12 1.13 ± 0.01 
T22G5.6 lbp-8 3.79 1.98 ± 1.23 
F40F4.3 lbp-1 0.94 1.06 ± 0.07 
EEED8.2 Fatty Acid Binding Protein 0.64 0.57 ± 0.06 
EEED8.3 Fatty Acid Binding Protein 1.83 ± 1.28 1.56 ± 0.48 
Y40B10A.1 Fatty Acid Binding Protein 0.96 1.20 ± 0.28 
C07E3.9 Phospholipase A2 0.86 1.03 ± 0.13 
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Gene ID Putative Function WT + 5mM 5HT aak-2 
C42D8.5 Angiotensin Conv Enzyme 1.09 0.68 ± 0.38 
C44B7.8 ATP Binding Protein 0.85 0.64 ± 0.01 
C25A1.5 Fatty-Acid Hydroxylase 0.50 ± 0.25 0.68 ± 0.18 
C44B7.9 Peroxisomal Membrane 2.12 0.82 ± 0.13 
Y56A3A.19 Acyl Carrier Protein 0.97 0.86 ± 0.10 
T02G5.7 Acetyl-CoA Acetyltransferase 0.84 0.88 ± 0.12 
T02G5.8 Acetyl-CoA Acetyltransferase 1.24 ± 0.12 1.07 ± 0.22 
C50D2.7 GlucoKinase 0.98 0.97 ± 0.22 
T08G2.3 Acyl-CoA Dehydrogenase 17.64 1.79 ± 1.31 
C55B7.4A Acyl-CoA Dehydrogenase 1.51 1.53 ± 0.19 
F28A10.6 Acyl-CoA Dehydrogenase 1.08 1.01 ± 0.11 
C02B10.1 Acyl-CoA Dehydrogenase 5.99 ± 4.55 1.86 ± 0.69 
E04F6.5 Acyl-CoA Dehydrogenase 1.39 1.79 ± 0.76 
C17C3.12A Acyl-CoA Dehydrogenase 1.27 1.10 ± 0.01 
F54D5.7 Acyl-CoA Dehydrogenase 0.70 0.40 ± 0.23 
F41C3.3 Acyl-CoA Synthase 0.93 0.82 ± 0.11 
T20B3.1 Carnitine Palmitoyl Transferase 3.32 ± 1.84 1.58 ± 0.46 
F09F3.9 Carnitine Palmitoyl Transferase 1.22 ± 0.25 0.55 ± 0.18 
K11D12.4 Carnitine Palmitoyl Transferase 10.98 1.74 ± 0.72 
Y48G9A.10 Carnitine Palmitoyl Transferase 1.30 0.95 ± 0.26 
W01A11.5 Carnitine Palmitoyl Transferase 0.74 0.46 ± 0.05 
F41E7.6 Carnitine Palmitoyl Transferase 1.28 ± 0.38 1.39 ± 0.50 
CARBOHYDRATE METABOLISM 
C05C10.3 Succinyl-CoA;3-ketoacid CoA 
Transferase 0.95 0.75 ± 0.11 
F25B4.6 HMG-CoA Synthase 0.98 0.78 ± 0.01 
Y71G12B.10 HMG-CoA Lyase 1.04 ± 0.26 0.75 ± 0.07 
F14B4.2 Hexokinase 0.69 ± 0.13 0.94 ± 0.07 
H25P06.1 Hexokinase 1.09 ± 0.39 0.93 ± 0.17 
Y71H10A.1 6-Phosphofructokinase (both 
spliceforms) 1.25 0.83 ± 0.41 
Y71H10A.1a 6-phosphofructokinase (a 
spliceform) 1.18 1.03 ± 0.14 
R11A5.4 PEPCK (all spliceforms) 1.06 0.89 ± 0.02 
W05G11.6 PEPCK (all spliceforms) 1.64 0.98 ± 0.19 
F25H5.3 Pyruvate Kinase (all 
spliceforms) 0.85 0.89 ± 0.03 
ZK593.1 Pyruvate Kinase 1.02 0.93 ± 0.09 
Y110A7A.6 Phosphofructokinase (both 
spliceforms) 0.65 0.77 ± 0.12 
K02B2.1 Phosphofructokinase 0.97 ± 0.34 0.83 ± 0.11 
T09F3.3 Glyceraldehyde-3 Phosphate 
Dehydroge 0.78 ± 0.32 2.0 ± 0.81 
F33H1.2 Glyceraldehyde-3 Phosphate 
Dehydroge 0.82 ± 0.35 0.59 ± 0.17 
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Gene ID Putative Function WT + 5mM 5HT aak-2 
R11A5.4a/b PEPCK (a and b spliceforms) 0.76 ± 0.19 0.69 ± 0.08 
R11A5.4a/c/d PEPCK (a, c and d isoforms) 0.96 0.94 ± 0.08 
W05G11.6a/d PEPCK (a and d spliceforms) 1.49 1.08 ± 0.33 
W05G11.6a/b/d PEPCK (a,b and d spliceforms) 1.15 0.87 ± 0.17 
W05G11.6a/b/c PEPCK (a,b and c spliceforms) 3.95 2.34 ± 1.29 
F25H5.3b Pyruvate Kinase (b spliceform) 4.31 ± 0.10 2.26 ± 1.07 
F25H5.3a/b Pyruvate Kinase (a and b 
spliceforms) 0.70 0.75 ± 0.04 
Y110A7A.6a Phosphofructokinase (a 
isoform) 0.88 1.19 ± 0.30 
H17B01.1b Sugar Transporter (b isoform) 4.24 ± 3.09 2.80 ± 2.25 
K07A3.1 fructose, 1,6 bisphosphatase 1.14 0.83 ± 0.20 
F54H12.1a/b aconitase (a and b spliceforms) 0.81 0.80 ± 0.07 
F54H12.1a/b/c aconitase (a, b and c 
spliceforms) 1.10 0.87 ± 0.01 
ZK455.1 aconitase 1.07 0.89 ± 0.17 
F20H11.3 malate dehydrogenase 1.06 0.98 ± 0.21 
F46E10.10a/c lactate/malate dehydrogenase 
(a and c) 0.73 0.99 ± 0.27 
F46E10.10a/b lactate/malate dehydrogenase 
(a and b) 0.77 0.86 ± 0.07 
C05E4.9.a Isocitrate lyase family/Malate 
synthase 1.53 1.09 ± 0.39 
C05E4.9.b Isocitrate lyase family/Malate 
synthase 1.23 1.18 ± 0.51 
C03G5.1 succinate dehydrogenase 1.11 ± 0.33 1.29 ± 0.38 
C34B2.7 succinate dehydrogenase 0.71 0.98 ± 0.27 
R11F4.1 glycerol kinase 0.93 ± 0.08 0.79 ± 0.10 
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Chapter II: Intestinal peroxisomal fatty acid β-oxidation 
regulates neural serotonin signaling through a feedback 
mechanism 
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Abstract 
The ability to coordinate behavioral responses with metabolic status is 
fundamental to the maintenance of energy homeostasis. In numerous species 
including C. elegans and mammals, neural serotonin signaling regulates a range of food-
related behaviors. However, the mechanisms that integrate metabolic information with 
serotonergic circuits are poorly characterized.   Here, we identify metabolic, molecular, 
and cellular components of a circuit that links peripheral metabolic state to serotonin-
regulated behaviors in C. elegans.  We find that blocking the entry of fatty acyl-CoAs into 
peroxisomal β-oxidation in the intestine results in blunting of the effects of neural 
serotonin signaling on feeding and egg-laying behaviors.  Comparative genomics and 
metabolomics revealed that interfering with intestinal peroxisomal β-oxidation results in a 
modest global transcriptional change but significant changes to the metabolome, 
including a large number of changes in ascaroside and phospholipid species, some of 
which affect feeding behavior.   We also identify body cavity neurons and an ether-a-go-
go related (EAG) potassium channel that functions in these neurons as key cellular 
components of the circuitry linking peripheral metabolic signals to regulation of neural 
serotonin signaling.  These data raise the possibility that the effects of serotonin on satiety 
may have their origins in feedback, homeostatic metabolic responses from the periphery. 
Introduction 
In both invertebrate and vertebrate species, behaviors such as feeding, movement, 
reproduction and learning are influenced by nutritional and metabolic signals [2–9].  In 
mammals, the nervous system actively monitors internal nutritional status by directly 
sensing specific metabolites like carbohydrates, amino acids and fatty acids, in addition 
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to sensing endocrine signals derived from peripheral tissues [10,11]. These internal 
nutrient cues are integrated with environmental stimuli and past experiences to 
orchestrate cohesive and context-appropriate behavioral and physiological responses. 
Defects in internal metabolic sensing processes contribute to the development of a 
number of disorders including diabetes, obesity, impaired immune function, 
neurodegeneration and accelerated aging [9,12–14]. Thus, elucidating the mechanisms 
by which nutrient status is sensed and communicated between tissues is of critical 
importance in understanding metabolic homeostasis as well as how metabolism 
influences myriad physiological and pathophysiological conditions.  
  Like mammals, C. elegans display a range of behavioral and physiological 
responses to changes in nutrient availability [2,15]. Moreover, as in vertebrate species, 
the neuromodulator serotonin, 5-hydroxytryptophan, is a key mechanism through which 
information about food availability is converted to behavioral, physiological, and metabolic 
responses in C. elegans [16–21].  For example, even in the presence of food, worms that 
lack serotonin display the feeding, egg laying, movement, and metabolic rates that are 
normally seen when wildtype animals are deprived of food [22]. In contrast, 
pharmacologic or genetic manipulations that elevate serotonin signaling elicit the range 
of responses seen when plentiful food supplies are present [20,23,24]. Importantly, 
serotonin signaling is not simply an on/off indicator of food availability but the extent of 
serotonin signaling allows for animals to fine tune their responses based on their 
nutritional status and past experiences [4,25,26].   One illustration of this is the effects of 
varying levels of serotonin signaling on pharyngeal pumping rate, the mechanism by 
which C. elegans ingest nutrients [27,28]. C. elegans that have been moved off of their 
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E. coli food source reduce their serotonin signaling as well as their pumping rates.  Both 
serotonin signaling and pumping rates are elevated as animals are returned to food  
[29,30].  However, if animals experience a period of fasting before they are returned to 
food, they exhibit an even further elevation in feeding rate compared to animals that have 
only been off of food for brief period of time. The hyper-elevated feeding behavior is 
accounted for by a correspondingly elevated secretion of serotonin from specific neurons 
[4]. The hyper-secretion of serotonin and the corresponding hyper-elevated feeding are 
transient and animals eventually resume the intermediate levels of serotonin signaling 
and feeding rates seen in well-fed animals [4,30].    Thus, the low, high, and intermediate 
levels of serotonin signaling correspond to the low, high, and intermediate pharyngeal 
pumping rates, respectively.  
 In addition to modulating of food intake behavior, serotonin signaling also affects 
energy metabolism [31]. C. elegans that have been returned to food after a period of 
fasting transition from a metabolic state that favors energy conservation to an active state 
of energy utilization.  This active metabolic state is driven by elevated serotonin signaling 
[19,32,33].  If elevated levels of serotonin are maintained by pharmacological or genetic 
interventions, C. elegans exhibit fat loss [34,35]. The effects of serotonin on body fat are 
not simply a byproduct of its effects on food intake as we and other groups have found 
that molecular and cellular circuits that link serotonin signaling to peripheral energy 
metabolism are largely independent from those that regulate feeding [19,23,24,32,33,36]. 
For example, serotonin secreted from the ADF sensory neurons signals through neurally 
expressed SER-5 serotonergic receptor to modulate feeding. Yet the SER-5 receptor is 
not required for the serotonergic regulation of peripheral fat metabolism [19,30]. Instead, 
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serotonin signals through the MOD-1 receptor on URX neurons to promote the release of 
a neuroendocrine signal that activates triglyceride lipolysis and distinct components of 
fatty acid oxidation pathways [19,32,33].    
  In a prior study, we discovered that specific components of lipid oxidation 
pathways can elicit regulatory effects on feeding behavior [19]. Here, we build upon that 
finding and describe a feedback mechanism that links peripheral energy metabolism to 
neuronal serotonin signaling.  We find that loss of ACOX-1, a peripheral acyl-CoA oxidase 
that catalyzes a key step in peroxisomal fat oxidation, affects feeding and egg-laying 
responses, two serotonin-regulated behaviors. Blunting the utilization of fatty acyl-CoA 
species, the metabolic substrates of ACOX-1, results in rewiring of peripheral metabolic 
pathways and ultimately affects the activity of body cavity neurons, which in turn, 
counteract neural serotonin signaling to influence nutrient-related behaviors.    
 
Results 
acox-1 mutants are unresponsive to the feeding stimulatory effects of serotonin 
While the serotonergic regulation of fat metabolism is largely distinct from the feeding 
regulatory pathway, we previously noted two exceptions.  RNAi-mediated inactivation of 
either acox-1, encoding a peroxisomal acyl-CoA oxidase, or cpt-6, encoding a 
mitochondrial carnitine palmityoltransferase, not only blocked the fat reducing effects of 
serotonin but also counteracted the effects of elevated serotonin on feeding [19].   
Interestingly, acox-1 and cpt-6 function as entry points in the peroxisomal and 
mitochondrial β-oxidation pathways, respectively [37]. To further investigate how 
metabolic pathways affect serotonin signaling, we focused on acox-1 given the 
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availability of a null mutant for this gene at the time that the study was undertaken.  
Recapitulating our prior RNAi findings, ad-libitum fed acox-1(ok2257) animals exhibit 
wildtype feeding rates, yet are unresponsive to the feeding stimulatory effects of 
exogenous serotonin (Figure 1A, Figure S1A). We previously demonstrated that 
elevated levels of serotonin signaling exert their effects on fat and feeding pathways by 
inactivating AMP-activated kinase (AMPK) complexes in distinct neurons [24,30].  As in 
mammals, the catalytic subunit of AMPK can be encoded by one of two distinct genes, 
aak-1 and aak-2, in C. elegans [38].  Elevated levels of serotonin signaling inactivate 
the AAK-2 subunit and the hyperactive pumping rate of serotonin-treated wildtype 
animals is recapitulated by aak-2 mutants [30].  Loss of acox-1 suppressed the elevated 
feeding rates of aak-2 mutants suggesting that the effects of acox-1 on feeding are not 
restricted to exogenously supplied serotonin (Figure 1B).  
Although the above findings suggested that acox-1 functions downstream or parallel to 
serotonin signaling, we sought to rule out the possibility that acox-1 affects serotonin 
biosynthesis.  Transcription of tph-1, the gene that encodes the rate-limiting enzyme of 
de novo serotonin synthesis, is highly dynamic and can be modulated by a range of 
external and internal cues including food availability, food quality, and stress [25,39–42]. 
We observed no changes in the transcriptional expression of tph-1 nor in direct 
quantifications of serotonin levels in acox-1 mutants (Figure S1B and S1C). In 
mammals, defects in peroxisomal fatty acid oxidation pathways are associated with 
neurodevelopmental disorders due to toxic accumulation of long and very-long chain 
fatty acids [43].  We had previously shown that elevation of serotonin signaling from the 
chemosensory, amphid ADF neurons is sufficient to cause elevated pharyngeal 
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pumping [30]. We therefore considered the possibility that the lack of response to 
serotonin in acox-1 mutants may be the indirect consequence of a defect in the ADF 
neurons or other sensory neurons. As one broad examination of neural morphology and 
development, we used DiI dye staining and found that acox-1 mutants had properly 
structured amphid sensory neurons (Figure S1D). Collectively, we found no evidence 
that deficiencies in serotonin biosynthesis or structural or developmental abnormalities 
in serotonergic sensory neurons account for the inability of serotonin to elevate feeding 
rate in acox-1 mutants.  
Based on homology to mammalian acyl-CoA oxidase 1, ACOX-1 is predicted to 
catalyze the first and rate-limiting step in peroxisomal β-oxidation [44,45].  We used 
fluorescence intensity of BODIPY labeled fatty acids as a measure of fat accumulation 
since we and others have previously demonstrated that BODIPY fluorescence 
corresponds to biochemical and label free methods, such as Coherent anti-Stokes 
Raman Scattering spectroscopy, measurements of fat content [46,47].  We found that 
animals lacking ACOX-1 accumulate significantly more fat in their hypodermis and 
intestines, the two major sites of fat storage, consistent with the notion that acox-1 
mutants have a reduced capacity to break down lipids (Figure 1C and 1D).  If the inability 
of acox-1 mutants to increase their feeding rate represented a homeostatic response to 
elevated internal energy stores, we predicted that a period of nutrient depletion should 
reverse acox-1 mutants’ feeding behavior. We fasted acox-1 mutants for 90 minutes, a 
period of time shown to elicit a coordinated shift in internal metabolic networks towards 
fat mobilization and energy production, and reintroduced fasted or ad-libitum fed animals 
to either vehicle or serotonin containing plates [48,49]. Fasting restored the ability of acox-
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1 mutants to increase their feeding rates in response to exogenous serotonin suggesting 
that acox-1 mutants do not simply have a generalized defect in pharyngeal pumping and 
that a period of starvation can reverse the feeding regulatory effect induced by loss of 
ACOX-1 activity (Figure 1E). Together, these findings suggest that loss of ACOX-1 
activity leads to the generation of a homeostatically regulated signal that can rapidly and 
reversibly modulate serotoninergic feeding circuits. 
 
Intestinal ACOX-1 regulates feeding behavior 
To elucidate the site of ACOX-1 activity in regulating feeding behavior, we 
performed tissue-specific rescue experiments. As previously reported, ACOX-1 is 
expressed in the hypodermis and the intestine, the primary sites of lipid metabolism in C. 
elegans [44] (Figure 2A). Expression of a full length wildtype acox-1 gDNA sequence in 
the intestine (via the vha-6 promoter) but not in the hypodermis (via the dpy-7 promoter) 
normalized fat levels in acox-1 mutants (Figure 2B and 2C). The intestine is the primary 
metabolic organ in C. elegans and carries out numerous metabolic functions including 
food digestion, nutrient absorption, packaging and secretion [50]. We found that the 
intestinal expression of wildtype acox-1 was sufficient to restore the capacity of acox-1 
mutants to elevate feeding rates in response to serotonin treatment (Figure 2D). Thus, 
intestinal ACOX-1 activity can affect neuronal serotonergic feeding circuits.  
 
Modulation of feeding by ACOX-1 requires fatty acyl-CoA synthesis  
Acyl-CoA oxidases regulate the rate of metabolic flux through peroxisomes as they 
govern the first and rate-limiting reaction in peroxisomal metabolic pathways, specifically 
catalyzing the desaturation of long and very-long chain fatty acyl-CoA esters to 2-trans-
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enoyl-CoAs [45,51–53].  The C. elegans genome encodes seven acyl-CoA oxidases that 
form homo and heterodimer complexes with distinct substrate specificities [51,54,55]. 
Structural and biochemical analyses suggest that ACOX-1 homodimers are capable of 
accommodating a wide-range of fatty acyl-CoA substrates and contribute to peroxisomal 
β-oxidation of ascaroside lipids [56,57]. Given the enzymatic function of ACOX-1, we 
hypothesized that its loss leads to an accumulation of fatty acyl-CoA species, which in 
turn, elicit the anorectic effect. Fatty acyl-CoAs are generated by acyl-CoA synthases 
(ACS), a family of enzymes that esterify free fatty acids with Co-enzyme A (CoA) [58,59]. 
To prevent the formation of acyl-CoA thioesters, we acutely exposed animals to Triacsin 
C, an inhibitor of acyl-CoA synthase activity [60]. This treatment restored the ability of 
serotonin to cause elevated feeding rate in acox-1 mutants suggesting that fatty acid 
esterification is required in order for ACOX-1 to regulate serotonergic feeding cascades 
(Figure 3A). There at least 20 known or predicted acyl-CoA synthases encoded in the C. 
elegans genome. As a strategy to validate the Triacsin C results and identify the specific 
synthases involved, we screened through 18 of 20 acs genes for which RNAi clones were 
available. RNAi treatment against multiple acs genes, most notably those of acs-18, acs-
20 or acs-22, suppressed the feeding defects of acox-1 mutants, suggesting that a degree 
of redundancy among C. elegans acyl-CoA synthases (Figure S3A).  As we did not 
validate the efficacy of each of the 18 RNAis we cannot rule out the possibility that other 
ACS enzymes also contribute to acyl-CoA pools used by ACOX-1.  To further test the 
notion that fatty acyl-CoAs modulate feeding, we treated animals with oleic acid, a dietary 
fatty acid, and noted a reduction in pharyngeal pumping rate (Figure 3B). The oleic acid-
induced feeding suppression was abrogated in animals that were pretreated with Triacsin 
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C, suggesting that the anorectic effect is induced by oleoyl-CoA or a downstream 
metabolic derivative.  
To directly evaluate whether loss of acox-1 causes accumulation of acyl-CoAs, we 
employed an HPLC-based extraction and detection method from whole animal extracts 
[61,62].   We found that acyl-CoAs levels were not grossly altered in acox-1 mutants 
(Figure 3C).   One possible explanation for the absence of elevated acyl-CoA species in 
acox-1 mutants is that only a small fraction of total acyl-CoAs in the animals are directed 
to peroxisomal β-oxidation such that a change in their abundance may not be detectable 
by our assay.  Moreover, acyl-CoA metabolism is known to be highly spatially regulated 
and acyl-CoA products are selectively synthesized or partitioned in specific tissues 
[63,64].  Yet another possibility is that acyl-CoAs are substrates for numerous metabolic 
processes and can be converted into a variety of signaling molecules like ceramides, 
ascarosides and eicosanoids [55,59,65].  Thus, blocking acyl-CoA utilization by 
inactivating ACOX-1 may shunt these intermediates into a variety of other metabolic 
derivatives that ultimately elicit anorectic effect. 
 
Loss of acox-1 results in modest transcriptional upregulation of compensatory fat 
oxidation pathways  
To better understand molecular responses to the loss of acox-1, we compared the 
transcriptome acox-1 mutants to that of wildtype animals using RNA-sequencing.  Loss 
of acox-1 had a surprisingly limited effect on global gene expression. Our analyses 
revealed that only 36 out of ~17,000 genes were differentially expressed in acox-1 
mutants, with only three genes significantly upregulated. Among the differentially 
expressed genes, the majority were expressed in the intestine, consistent with our finding 
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that this tissue is a major site of action for ACOX-1. Gene Ontology analysis revealed an 
enrichment for genes involved in “lipid metabolic” and “innate immune” related processes 
(Table 1). Among the differentially regulated genes, several are predicted to encode for 
components of peroxisomal β-oxidation including a homolog of acyl-CoA oxidase (ACOX-
2), an enoyl-CoA hydratase (ECH-1.1) and an ortholog of human bile acid-CoA:amino 
acid N-acyltransferase (K05B2.4).   Two lipases, LIPL-2 and K03H6.2, whose activities 
are predicted to promote lipid mobilization, were downregulated. Collectively, we interpret 
these results to mean that the transcriptional responses elicited upon loss of acox-1 likely 
compensate for peroxisomal dysfunction by limiting lipid mobilization and by upregulating 
alternative lipid utilization pathways. Using RNAi, we asked whether inactivation of any of 
the upregulated genes could counteract the resistance of acox-1 mutants to serotonin 
induced feeding elevation but the experiment yielded no such candidates.    
 
Loss of acox-1 perturbs fatty acid ethanolamine signaling 
Next, we sought to obtain a comprehensive overview of the impact of loss of acox-
1 on the C. elegans metabolome. For this purpose, we compared the acox-1 mutant and 
wildtype metabolomes via untargeted metabolomics using high-pressure liquid-
chromatography-high-resolution mass spectrometry (HPLC-HRMS) and the XCMS 
software platform [66,67]. These analyses revealed that knockout of acox-1 has a 
dramatic impact on the C. elegans metabolome. Of more than 10,000 significant features 
detected in the wildtype metabolome, over 500 were at least 3-fold downregulated in 
acox-1 mutants. Conversely, we detected more than 500 features that were at least 3-
fold upregulated in acox-1 mutants. To facilitate structural classification of the vast 
number of detected differential features, we employed molecular networking based on 
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analysis of MS/MS fragmentation patterns [68,69]. These analyses enabled 
characterization of several metabolite families up- or downregulated in acox-1 mutants. 
As expected from previous reports, we found that biosynthesis of most ascaroside 
pheromones with fatty acid side chains shorter than 9 carbons is abolished or strongly 
reduced in acox-1 mutants, whereas abundances of ascarosides with saturated side 
chains of 9 to 15 carbons are 10- to 50-fold increased [56,57]. In addition, a large number 
of diacylglycerophosphoethanolamines (DAGPEs), primarily derived from saturated and 
mono-unsaturated fatty acids with 14 to 18 carbons, were reduced 5- to 20-fold in acox-
1 mutants. Among the metabolites most strongly upregulated in acox-1 mutants, thiamine 
and several thiamine derivatives were most prominent, alongside ascr#18 and ascr#22, 
ascarosides with 11 and 13 carbon sidechains, respectively (Figure 4, Supplemental 
Table 1).   
 The very large number of metabolites affected by loss of acox-1 prevented a 
comprehensive examination of each of the metabolites.  Nevertheless, we used a 
combination of chemical, genetic, and metabolite add-back experiments to broadly 
investigate the noted metabolomics changes.   We began by considering the possibility 
that perturbations in ascaroside biosynthesis underlie the feeding defect observed in 
acox-1 mutants.  Originally identified as constituents of the dauer pheromone, 
ascarosides are large class of excreted small molecules that regulate development and 
behavior and whose synthesis can be influenced by metabolic status [70–72].   The acyl-
CoA thiolase, DAF-22, catalyzes the terminal step in peroxisomal β-oxidation and plays 
an essential role in shortening the fatty acid-like-side chains of ascarosides [73]. Though 
daf-22 mutants lack ascarosides they still exhibit wildtype feeding rates and are still 
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responsive the feeding increasing effects of serotonin, suggesting that ascaroside 
biosynthesis and serotonergic feeding regulation are independent of one another (Figure 
S4A). Though a number of ascaroside species were strongly reduced in acox-1 mutants, 
we detected a nearly 30-fold accumulation of ascaroside #18 (ascr#18). To determine if 
an accumulation of ascr #18 underlies the suppressed feeding response of acox-1 
mutants, we treated wildtype animals with ascr#18 and serotonin. Surprisingly, rather 
than suppressing feeding, ascr#18 dramatically increased pharyngeal pumping rates of 
wildtype animals in a manner that was additive with serotonin (Figure S4B).  Together, 
these results suggest that while certain ascarosides species can have feeding regulatory 
effects, they are unlikely to underlie the specific feeding responses elicited in acox-1 
mutants.  
Thiamine and thiamine derivatives were also significantly accumulated in acox-1 
mutants.  We next asked if thiamine supplementation was sufficient to block the feeding 
enhancing effects of serotonin, though did not find this to be the case (Figure S4C).  As 
in mammals, C. elegans does not produce thiamine and obtains this essential cofactor 
from its diet [74]. Given the pervasive changes to C. elegans metabolism upon loss of 
acox-1, we speculate that thiamine accumulation in these mutants reflects a general 
downregulation of enzyme activities that use thiamine derivatives as cofactors. 
 We next turned our attention to the finding that loss of acox-1 perturbs the 
biosynthesis of ethanolamine containing lipid species. Most prominently, we find that 
diacylglycerophosphoethanolamine (DAGPEs) synthesis is strongly reduced in acox-1 
mutants. DAGPEs likely represent intermediates in the biosynthesis of N-
acylethanolamines (NAEs), a diverse family of signaling molecules with range of 
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biological roles including in nutrient sensing and mammalian appetite regulation [75–79]. 
This family of lipids includes the mammalian orexigenic endocannabinoid arachidonoyl 
ethanolamine (AEA) and anorectic factor oleoyl ethanolamine (OEA) [80]. To test if a 
reduction in NAEs contributes to ACOX-1 mediated feeding regulation, we inactivated 
fatty acid amide hydrolase (faah-1), an enzyme involved in the hydrolytic degradation of 
NAEs. We found that inhibition of FAAH-1, which was shown to increase endogenous 
NAE abundance [81], stimulates pharyngeal pumping rates of both wildtype and acox-1 
mutants (Figure S4D). Thus, in C. elegans as in mammals, NAE signaling regulates 
feeding behavior.  As the feeding increasing effects of increasing NAEs were not 
restricted to acox-1 mutants, we cannot definitively know that reduced NAE synthesis 
accounts for the inability of acox-1 mutants to respond to serotonin.  Though this data is 
intriguing, it is also possible that an as of yet unidentified metabolite or a complex 
combination of metabolites blunt serotonergic modulation of feeding in acox-1 mutants.  
 
ACOX-1 mediated regulation of serotonergic feeding circuits requires EGL-2 
activity 
We next sought to identify the neural mechanisms that link changes elicited by loss 
of acox-1 to serotonergic mechanisms of feeding. The clue that guided us towards an 
answer emerged unexpectedly by following another phenotype that we had noted in acox-
1 mutants.  Relative to wildtype animals, acox-1 mutants hold more eggs in utero and lay 
embryos at a later developmental stage (Figure 5A, Figure S4A).  This was intriguing 
since serotonin is also a key modulator of egg-laying behavior [82]. Serotonin controls the 
excitability of the egg-laying neuromuscular circuit and governs the activity and timing of 
egg-laying in response to various sensory cues [16–18,83–88]. We found that acox-1 
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mutants were markedly less responsive to exogenous serotonin and resistant to the 
effects of fluoxetine, a serotonin reuptake inhibitor consistent with a reduced response to 
the excitatory effects of serotonin at the level of the neuromuscular junction (Figure 5C, 
Figure S4B). As in the context of feeding, reconstitution of acox-1 in the intestine but not 
the hypodermis also rescued egg-laying defects of these mutants (Figure 5D and 5E).   
The egg-laying neuromuscular circuit has been extensively studied in C. elegans 
and it is well established that egg-laying behavior is strongly influenced by potassium 
channel activity [89]. Potassium channels are a highly diverse and evolutionarily 
conserved family of proteins that modulate cellular excitability by regulating the flow of 
potassium ions (K+) across cellular membranes [90,91]. Gain-of-function mutations in 
distinct potassium channels have been shown to reduce the excitability of neurons or 
vulval muscles, and in turn causing egg-laying defects [92–95]. We therefore considered 
the possibility that aberrant potassium channel activity contributes to the egg-laying 
dysfunction in acox-1 mutants.  We conducted an RNAi screen of potassium channels 
with documented roles in egg-laying and assessed their capacity to rescue the egg-laying 
defect in acox-1 mutants.  RNAi knockdown of the EGL-2 potassium channel normalized 
egg-laying responses in acox-1 mutants without influencing baseline egg-laying rates 
(Figure S4C and S4D). To validate our RNAi results, we crossed acox-1 mutants with egl-
2(lf) mutants and found that double mutants resembled wildtype animals in their egg-
laying responses (FIGURE 5F and 5G).  egl-2 encodes an ether-a-go-go (EAG) voltage-
gated potassium channel that has been shown to modulate the excitability of 
neuromuscular circuits in response to starvation states, suggesting they may more 
generally serve as a link between internal nutrient status and neuronal activity [96–98].  
 71 
To determine if EGL-2 plays a role in ACOX-1 mediated feeding regulation, we 
took advantage of gain-of-function mutations in egl-2. These mutations cause a negative 
shift the voltage-dependence of these channels and cause pleotropic sensory and 
behavioral defects by reducing the excitatory capacity of cells in which they are expressed 
[99,100]. It has been previously reported that egl-2(gf) mutants are resistant to the egg-
laying inducing effects of serotonin [95,101]. We find that egl-2(gf) mutants are also 
resistant to the feeding enhancing effects of serotonin and thus mimic acox-1 mutants in 
their blunted responses to the excitatory effects of serotonin signaling in the context of 
both egg-laying and feeding (Figure 6A). Both the egg-laying and pharyngeal pumping 
phenotypes of egl-2(gf) mutants can be fully suppressed by egl-2 RNAi knockdown 
suggesting that the behavioral effects of aberrant EGL-2 activity can be normalized by 
inactivating the channel (Figure 6A, Figure S5A). Similarly, RNAi inactivation of egl-2 
restores the ability of acox-1 mutants to elevate their pumping rates upon exposure to 
serotonin signaling but without affecting the basal pumping rate in acox-1 mutants (Figure 
6B). Validating the RNAi results, we find that double acox-1;egl-2(lf) mutants exhibit 
wildtype feeding responses to exogenous serotonin (Figure 6C). Finally, we find that the 
feeding reducing effects of oleic acid also require EGL-2 (Figure 6D). Together, these 
results suggest that an EGL-2 containing circuit can serve as a regulatory link between 
metabolic status and feeding behavior.  
 
Loss of acox-1 suppresses URX body cavity neuron activity to limit feeding 
responses 
Our results with egl-2 provided us the opportunity to pinpoint neurons that may 
serve as a link between peripheral metabolic signals and processes regulated by 
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serotonin signaling.  In hermaphrodites, egl-2 is expressed in a limited subset of sensory 
neurons including AFD, ALN, AQR, ASE, AWC, BAG, IL2, PLN, PQR and URX [99]. We 
were intrigued by the expression of egl-2 channels in body cavity neurons (AQR ,PQR 
and URX), as these are the only neurons with dendritic projections within the 
pseudocoelom, the rudimentary circulatory fluid utilized by C. elegans (Figure 7A) [102]. 
Given their unique anatomic position, these neurons are hypothesized to mediate 
bidirectional communication between nervous system and peripheral tissues as they have 
the capacity to both release and detect circulating signals. Interestingly, neural serotonin 
signaling is thought to promote intestinal fat metabolism through the release of an 
neuroendocrine signal from URX neurons [32,33] and fluctuations in peripheral fat 
metabolism modulate the tonic activity of URX [103]. We find that targeted expression of 
egl-2(gf) in only the body cavity neurons is sufficient to block the feeding increasing effects 
of serotonin and mimic the effects of loss of acox-1 (Figure 7B).  
To our knowledge, body cavity neurons have not previously been implicated in the 
regulation of feeding behavior. To further study this role, we examined the effect of 
prolonged activation of body cavity neurons on pharyngeal pumping. Activation of PKC-
1 has been shown to promote synaptic transmission and neuropeptide release from 
expressing neurons [104]. We examined the feeding responses of wildtype and acox-1 
mutants expressing constitutively active protein kinase C [PKC-1(gf)] in body cavity 
neurons and found that this manipulation strongly stimulates pharyngeal pumping in both 
wildtype and acox-1 mutants. Importantly, this feeding enhancement could not be further 
elevated by addition of serotonin, suggesting a common regulatory circuit (Figure 7C).  
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As genetic inhibition of body cavity neurons by egl-2(gf) did not modulate baseline feeding 
rates, our data suggests that these neurons likely fine-tune feeding responses in distinct 
conditions rather than governing basal feeding behavior.  
To directly assess the effects of ACOX-1 activity on body cavity neuron function, 
we measured intracellular Ca2+ transients from the URX body cavity neurons using the 
genetically-encoded calcium reporter GCaMP5K [103,105]. We selected URX neurons 
as calcium dynamics from these cells have been well documented and intriguingly their 
activity has recently been shown to be modulated by internal metabolic cues and 
starvation [103,106–108]. URX neurons play a well-documented role in oxygen sensing 
and are robustly and rapidly activated under atmospheric conditions (21% oxygen) 
(Figure 8A and 8C) [106,109–111]. To determine if loss of ACOX-1 modulates URX 
activity, we imaged O2-evoked calcium transients in URX neurons in wildtype and acox-
1 mutants. We observed no significant difference in URX responses in wildtype and acox-
1 mutants at 10% oxygen, a concentration at which the tonic URX neurons are held in the 
“off” state [106]. This result suggests that ACOX-1 does not modulate basal activity of 
URX (Figure 8B and 8F). However, whereas URX neurons in wildtype animals robustly 
activate at 21% oxygen as previously documented, O2-evoked calcium transients were 
dramatically inhibited in acox-1 mutants (Figure 8D and 8D). This reduction in maximal 
activation (F∆/Fo) could not be attributed to altered promoter activity or drift in expression 
across the tested lines as the level of a co-expressed flp-8::mCherry reporter was not 
measurably different acox-1 mutants (Figure 8E and 8G). Together, this data suggest that 
loss of ACOX-1 decreases the sensitivity of URX neurons to excitatory stimuli, supporting 
the model that body cavity neuron activity is suppressed in acox-1 mutants  
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We previously showed that regulation of feeding responses by ACOX-1 requires 
the generation of fatty acyl-CoA species. We thus asked whether we could rescue the 
suppression of URX neuron activity by inhibiting the synthesis of fatty acyl-CoA species.  
To assess the effects of fatty acyl-CoA species on URX activity, we treated wildtype and 
acox-1 animals with the acyl-CoA synthase inhibitor, Triacsin C for 60 minutes prior to 
assessing URX responses. Paradoxically, reducing the synthesis of fatty acyl-CoAs 
suppresses the activity of URX neurons in wild-type animals but slightly enhances the 
activity of this neuron in acox-1 mutants though these trends are not statistically 
significant (Figure S6).  
These results are complicated to interpret. Though this experiment suggests that 
Triacsin C does not significantly rescue the defects in URX activity, we must consider the 
limitations of this experimental approach. GCaMPs are powerful tools, they offer indirect 
and oft-crude representations of neuronal activity that lack in spatial and temporal 
resolution. It possible that our particular methodology and experimental set up is not 
sensitive enough to resolve the small but perhaps biologically relevant increase in URX 
activity in acox-1 mutants treated with Triacsin C. Of particular relevance to this study, 
the electrophysical properties of neurons cannot easily be interpreted from GCaMP 
recordings. Our model suggest that ACOX-1 may influence body cavity neuron activity in 
a mechanism involving EGL-2 potassium channels. Potassium channels play significant 
roles in shaping the frequency, duration and firing pattern of action potentials and it is not 
entirely clear how these properties are reflected at the level of Ca2+ dynamics. To clarify 
the influence of fatty acyl-CoAs on URX neurons, it will be necessary to use alternative 
reporters of URX neuronal activity. Body cavity neurons are peptidergic neurons as it has 
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been reported that  activity of these neurons can be assessed by monitoring the secretion 
of fluorescently-tagged neuropeptides[107]. This read-out may offer a more 
physiologically representative and sensitive measure of URX activity.  
Our data supports a model in which loss of ACOX-1 leads to the generation of a 
metabolic signal derived from a fatty acyl-CoA that regulates the activity of the URX body 
cavity neuron in an EGL-2 dependent manner. In turn, this circuit modulates the 
excitability of serotonergic circuits to link internal metabolic information with behavioral 
responses.  
 
Discussion 
 Animals adopt distinct behavioral and physiological states in response to changes 
in internal metabolic status. In this study, we show that peripherally generated signals act 
to modulate neurally regulated processes in C. elegans.  Specifically, we found that loss 
of an intestinal peroxisomal acyl-CoA oxidase leads to the production of interoceptive 
signals of metabolic status that modulate serotonergic regulation of feeding and egg 
laying.  These signals are generated when acyl-CoAs that would normally be destined for 
peroxisomal β-oxidation via ACOX-1 are redirected into other pathways resulting in a vast 
change to the animal’s metabolome despite a very modest transcriptional effect.  
Moreover, we found that the metabolic changes in the periphery affect the activity of a 
specific neuron, URX, a ring neuron that is anatomically well positioned to sense 
peripheral signals.  A change in the activity of URX dampens the effects of elevated 
serotonin signaling on feeding and egg laying.  The precise mechanisms by which URX 
neurons intersect with serotonergic circuits of feeding and egg-laying remain to be 
determined. 
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Our genetic and pharmacological analyses suggest that the feeding regulatory 
response begins with an accumulation of a fatty acyl-CoA species. Physiological condition 
in which generation of acyl-CoAs exceeds their utilization predicted to occur during 
periods of nutrient excess, thus the feeding reducing effects of these signals are 
consistent with satiety-like signals. In mammals, pharmacologic or dietary manipulations 
that lead to elevated circulating fatty acyl-CoA levels inhibit food intake [112,113]. Fatty 
acyl-CoAs are short-lived species that are substrates for numerous enzymatic pathways 
and it is unclear in mammals whether the anorectic effect is mediated directly by specific 
fatty acyl-CoAs or  downstream metabolic derivatives [114]. While we could not measure 
an obvious increase in acyl-CoA pools extracted from acox-1 mutants, our metabolomic 
analyses revealed many hundreds of differentially expressed features in acox-1 mutants, 
the majority of which remain structurally unidentified. The enormous metabolomic change 
made it unrealistic for us to pinpoint the precise metabolic species that underlies the 
effects of loss of acox-1 on serotonergic signaling.   Nevertheless, our metabolomics 
analyses revealed several classes of compounds including a variety of phospholipid 
species that may underlie the noted behavioral changes. Several  N-acylethanolamines 
have well-known effects on mammalian feeding behavior and mood [79,115–118].  Their 
identification here highlighting the deep evolutionary origins of the links between 
metabolic state and neural mechanism that influence behavior.   
We found that body cavity neurons, most prominently URX, serve as key 
components of the sensory circuit linking peripheral metabolic information with feeding 
behavior. Body cavity neurons are known to regulate oxygen sensing and social 
aggregation behaviors though to our knowledge they have not been implicated in 
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regulation of pharyngeal pumping [109,111,119,120]. Given their unique anatomical 
placement, these neurons have long been hypothesized to facilitate bi-directional 
communication between the nervous system and peripheral tissues, particularly in the 
context of energy homeostasis. Several lines of evidence, in addition to our findings, offer 
experimental credence to this hypothesis. First, these neurons are in direct synaptic 
contact with environment sensing neurons like ADF and release modulatory signals to 
influence peripheral processes such as body growth, lifespan control and lipid metabolism 
[103,107,121,122]. Second, these neurons have the capacity to sense internal metabolic 
cues and integrate this information with external cues of nutrient availability to orchestrate 
cohesive and context-appropriate physiological responses [103]. Lastly, our data and a 
recent study suggest that internal nutrient sensing pathways modulate the activity of these 
neurons to regulate nutrient-dependent behavioral states [123]. Skora et al. suggest that 
prolonged nutrient deprivation increases the activity of URX neurons to control starvation-
induced quiescence behaviors in a mechanism that involves DAF-2/IGF signaling. This 
data complements our findings and suggests that states of nutrient excess and nutrient 
deprivation have inverse effects on URX activity.   
An important future challenge is to determine how the vast metabolic changes in 
the periphery are sensed by the body cavity neurons including URX.  In principle, it is 
possible that some of the peripheral metabolites leave their intestinal sites of generation 
to directly act on the URX neurons.  Alternatively, it is possible that an endocrine response 
originating in the intestinal cells communicates the metabolic status of the intestine to the 
URX neurons.   Regardless of which model may ultimately be valid, our findings point to 
egl-2 as a modulator of URX activity.  EGL-2 is a C. elegans potassium channel with close 
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homology to human ether-a-go-go related channels [99,124].  While mammalian EAG 
channels have not yet been implicated in the control of nutrient-dependent behavioral 
plasticity, numerous potassium channels have well-documented roles in metabolic 
sensing and energy homeostasis. For example, hypothalamic Kir6.2 KATP channels are 
responsive to circulating glucose levels and regulate appetite and glucose homeostasis 
[125–127]. Ketogenic diets, which increase circulating ketone body levels, have been 
shown to suppress the excitability of GABAergic neurons and reduce seizure 
susceptibility in a KATP channel dependent manner [128–130].  Numerous metabolites 
including phospholipids, polyunsaturated fatty acids, eicosanoids, fatty acyl-CoAs and 
oxygen can directly bind certain potassium channels to modulate channel activity [131–
133]. Alternatively, metabolic information can be coupled to potassium channels by 
indirect signaling events involving second messengers like Ca2+ and cAMP, 
neurotransmitters or post-transcriptional modifications [134,135].     
In both mammals and C. elegans, elevating serotonin signaling is associated with 
fat loss [19,34,35,136].  In mammals, this has been primarily attributed to the anorectic 
effects of serotonin.  By contrast, detailed analysis of serotonergic effects in C. elegans, 
revealed that distinct molecular mechanisms underlie the fat and feeding effects of 
serotonin and that serotonin induced fat reduction in C. elegans is primarily driven by 
upregulation of peripheral mechanisms of triglyceride lipolysis and β-oxidation [19,32,33].  
Although it is general overshadowed by the feeding behavioral data, the existing data 
indicate that serotonin also causes an increase in metabolic rate and increase fat 
oxidation in mammals [31,137–139].  In this study, we found that if β-oxidation pathways 
cannot utilize the influx of acyl-CoAs that are generated upon mobilizing stored 
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triglycerides, a homeostatic signal is generated to blunt serotonergic effects, including 
effects on feeding.  The complexity of the mammalian fat and feeding pathways has made 
it difficult to pinpoint the precise mechanisms through which serotonin levels act as satiety 
signals.  Our findings raise the possibility that in both worms and mammals, increasing 
serotonin signaling may result in peripheral metabolic changes that, in turn, feedback to 
the nervous system to modulate food intake.  
 
Materials and Methods 
 
Worm Strains and General Maintenance 
C. elegans strains were cultured under standard growth conditions [140]. The Bristol N2 
strain was used as wildtype in all experiments and the following mutant alleles and 
transgenic strains were analyzed: acox-1(ok2257), aak-2(ok524), egl-2(rg4), egl-
2(n2656), daf-22(m130),  CX10386 kyEx2491[gcy-36::pkc-1(gf)::SL2::GFP; ofm-
1::dsRed], SSR1070 flp-8::mCherry; flp-8::GCaMP5k. When generating double mutants, 
genotypes were confirmed by PCR or sequencing. Unless stated otherwise, animals were 
cultured on NGM agar plates with OP50 E. coli at 20oC. For all experiments, worms were 
plated as synchronized L1 populations after hypochlorite treatment of gravid adults.  
Plasmid construction and transgenesis 
Plasmids were constructed using Gateway Cloning Technology (Life Technologies). 
Promoter regions were amplified from wildtype genomic DNA using Phusion DNA 
polymerase (New England Biolabs) and sub-cloned into the pDONR-P4-P1R Gateway 
entry vector by BP recombination. Unless otherwise specified, primers pairs were 
designed based on Promoterome recommendations. For acox-1 tissue specific rescue 
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lines, full F08A8.1 genomic coding sequence was amplified from wildtype genomic DNA 
was subsequently sub-cloned into the P221 Gateway entry vector by BP recombination. 
Transgenic animals were generated by injecting purified plasmids into the gonads of 
wildtype or mutant animals. Transgenes and an unc-122::gfp co-injection marker were 
injected at a concentration of 50 ng/μl. At least two independent and stably expressing 
lines were maintained and analyzed.  
Serotonin, Fluoxetine, Oleic Acid and Triacsin C Treatments 
Stock solutions of serotonin hydrochloride (TCI America, S0370) and fluoxetine 
hydrochloride (Matrix Scientific, 047891) were prepared in water.  For feeding 
experiments, synchronized L1 animals were grown on OP50 plates containing 5mM 
serotonin and assayed at the day 1 adult stage. To determine egg-laying responses, 
animals were exposed to 0.5mg/mL fluoxetine in M9 buffer or 5mg/mL serotonin in M9 
buffer for 20 minutes prior to counting released eggs. Oleic acid and Triacsin C treatments 
were conducted as previously described [19]. Briefly, Oleic Acid (Sigma-Aldrich, O1383) 
was solubilized in 45% (w/v in dH2O) 2-hydroxypropyl-ß-cyclodextrin (Sigma-Aldrich, 
H5784) to 1M, and then added to OP50 plates to a final concentration of 1µM. Triacsin C 
(Enzo Life Sciences, BML-EI218) was solubilized in DMSO and used at 1µM on OP50 
plates. 
Pharyngeal Pumping  
Contractions of the posterior pharyngeal bulb were counted during a 10 second interval 
as previously described [19]. For measurements on fasted then refed animals, ad-libitum 
fed day 1 adults were washed 3 times in S-basal buffer to remove residual E. coli and 
subsequently placed on sterile NGM plates. Animals were fasted on plate for the indicated 
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time then transferred to either vehicle (OP50 E. coli) or treatment (5mM serotonin + OP50) 
containing plates for 90 minutes to assay post-fast feeding responses.  
RNAi Treatment 
Overnight cultures of HT115 E. coli containing RNAi plasmids were induced with 6mM 
IPTG for 4 hours at 37oC. Cultures were concentrated 2X and added to RNAi plates 
containing IPTG, carbenicillin, and tetracyclin. Synchronized L1 animals were added to 
plates and grown for 3 days at 20oC and assayed as day 1 adults.  
Microscopy 
Animals were mounted on 2% agarose pads, paralyzed with NaN3 and imaged using a 
Zeiss Axioplan 2 microscope with a 16X (0.55 NA) oil immersion objective. DIC images 
of eggs retained in utero were acquired from animals at the Day 1 adult stage.   
Acyl-CoA Quantification 
We adapted an HPLC-based acyl-CoA extraction, derivatization and quantification 
protocol from Larson et al., 2008 [62]. Briefly, 15,000 synchronized L1s were grown in 
liquid S-medium culture at 20°C on a rotary shaker. Animals were grown to the L4 stage 
and washed 3X in S-Basal then snap frozen in liquid nitrogen and stored at  -80°C until 
further processing. To prepare lysates, pellets were thawed on ice and resuspended in 
300µL of freshly prepared extraction buffer (2mL 2-propanol, 2mL pH 7.2 50mM KH2PO4, 
50µL glacial acetic acid, 80µL 50mg/ml BSA). ~500 mg of zirconium oxide beads 
(NextAdvance, 0.5 mm diameter, 5.5 g/ml) were added to each sample and animals were 
lysed using a bead beater (5 cycles - 30s ON, 1 min OFF) at 4 °C. Lysates were separated 
from beads by pipet and an aliquot was preserved for protein quantification (Bio-Rad, DC 
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Protein Assay). Lysates were then washed of lipids and pigments in 200µL petroleum 
ether (40-60°C) saturated 1:1 with 2 propanol:water. 5µL of saturated (NH4)2SO4 was 
added to samples before extracting acyl-CoAs with 600µL 2:1 methanol:chloroform. 
Samples were vortexed and incubated at room temperature for 30 minutes before 
centrifugation. Supernatants were transferred to glass tubes and dried at 40°C in a 
GeneVac (~2hrs). Once dry, samples were reconstituted in 55µL of chloroacetaldehyde 
derivatizing reagent (0.15 M sodium citrate, 0.5% SDS (w/v), 0.5 M chloroacetaldehyde, 
pH 4) and incubated in an 80°C water bath for 20 minutes. Samples were again clarified 
by centrifugation, before being transferred to HPLC sample tubes. 20µL of each sample 
was injected into an equilibrated C18 reversed-phase HPLC column (Phenomenex Luna, 
4.6 mm x 150 mm, 5 µm silica particle, 100 Å pore size). A linear gradient of 0.25% (v/v) 
triethylamine in water and 90% (v/v) acetonitrile in water at a 0.5mL/min flow rate was 
used to elute acyl-CoAs. Full elution protocol described in [62]. Derivatized acyl-CoAs 
were detected using a fluorimeter with flash rate 100Hz and with excitation wavelength at 
230nM, emission wavelength at 420nM and slid width at 20nM. Peak areas were 
integrated and quantified using Agilent ChemStation software. 
RNA-Seq Sample Preparation  
Total RNA was extracted from ~10,000 synchronized L4 animals using the standard 
Trizol, chloroform, isopropanol protocol with on-column DNAse digest. Sample quality 
and quantity were assessed on the Agilent Bioanalyzer using RNA 600 Nano chips and 
only samples with RIN score ≥9 were used for library construction. mRNA was enriched 
from 1µg of total RNA using NEXTflex™ Poly(A) Beads (Bioo Scientific, NOVA-512979) 
and strand-specific directional libraries were generated using the NEXTflex™ Rapid 
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Directional RNA-Seq Kit (Bioo Scientific). For each genotype, samples were prepared 
from 3 biological replicates and indexed with distinct barcodes. Quality and fragment size 
distribution of synthesized cDNA libraries were assessed on the Agilent Bioanalyzer using 
DNA 1000 chips. Library concentrations were quantified using the NEBNext Library Quant 
Kit (E7630S) and each library was normalized to 10nM in TE buffer prior to pooling. 
Multiplexed libraries were sequenced using 100bp pair-end reads on the Illumina HiSeq 
4000 platform at the UCSF Center for Advanced Technologies.  
RNA-Seq Analysis  
Transcriptomic analyses were performed on the Galaxy Platform [141]. Sequencing reads 
were filtered and trimmed to remove barcode sequence using fastx_trimmer 
(http://hannonlab.cshl.edu/fastx_toolkit/). Clipped paired-end sequences were aligned to 
the C. elegans ce11 reference genome using TopHat version 2.1.1 [142]. Read counts 
for each gene were quantified using htseq-count based on gene annotations from 
reference annotation WS235 [143]. Differential expression analysis was conducted using 
the DESeq2 package (3.8) in R(3.4.1) using size factor normalization [144]. P-values 
were adjusted for multiple comparisons using the Benjamini-Hochberg method and a 
permissive false discovery threshold of q ≤ 0.1 was applied to identify differentially 
expressed transcripts.   
Metabolomic sample preparation 
Mixed stage worms were grown in liquid and fed OP50 on days 1, 3 and 5 during the 7-
day culture period, while shaking at 22 °C and 220 rpm. The cultures were centrifuged at 
4 °C, and worm pellets and supernatant were frozen separately, lyophilized, and each 
extracted with 35 mL of 95% ethanol at room temperature for 12 h. The extracts were 
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dried in vacuo, resuspended in 200µL methanol, and analyzed by LC-HRMS. All cultures 
were grown in at least three biological replicates. 
Mass spectrometric analysis 
LC-MS analysis was performed on a Dionex 3000 UHPLC coupled with a 
ThermoFisher Q Exactive high-resolution mass spectrometer. Metabolites were 
separated using a water–acetonitrile gradient on Agilent Zorbax Eclipse XDB-C18 column 
(150 mm x 2.1 mm, particle size 1.8 µm) maintained at 40 °C. Solvent A: 0.1% formic acid 
in water; Solvent B: 0.1% formic acid in acetonitrile. The solvent gradient started at 5% B 
for 5 min after injection and increased linearly to 100% B at 12.5 min, and continued at 
100% B for 5 min. The gradient was rapidly brought down to 5% B (over 30s) and held 
for 2 min for re-equilibration. 
The UHPLC-MS data were collected in the profile MS mode, based on instrument 
specifications. Metabolites were detected as [M-H]- ions or [M+Cl]- adducts in the negative 
ionization mode (ESI+), or as [M+H]+ ions or [M+Na]+ adducts in the positive ionization 
mode (ESI+), using a spray voltage of 3 kV. Compound identities were confirmed based 
on their high-resolution masses (accuracy < 1 ppm), MS/MS fragmentation spectra, 
and/or comparison with authentic standards. Data analysis was carried out using the 
Bioconductor package XCMS [66,145]. The matched filter algorithm in XCMS for peak 
picking in the profile data was used. 
GCaMP Calcium Imaging 
Animals were exposed to different oxygen concentration (10% or 21%) using a 
microfluidic chamber constructed with the oxygen-permeable poly(dimethylsiloxane) 
(PDMS) as described [106]. A Valvebank II (AutoMate Scientific, Inc.) was used to control 
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input from two pressurized pre-mixtures of oxygen and nitrogen containing either 10% 
oxygen or 21% oxygen (Praxair, Inc.). The gas flow rate was measured by a VWRTM 
traceable pressure meter and set to 0.26 psi. At the time of experiment, an individual day 
1 adult animal was picked without using any food and consecutively transferred to two 
unseeded plates immediately before imaging. The transferred animal was immobilized in 
S basal containing 5 mM levamisole and transported into the microfluidic chamber via 
Tygon tubing (Norton). To avoid drying, the animal was constantly submerged in S-Basal 
buffer while inside the chamber and GCaMP5K fluorescence was visualized at 40x 
magnification using a spinning disk confocal microscope (Olympus) with MetaMorphTM 
software (version 6.3r7, Molecular Devices). As described earlier, worms were pre-
exposed to 10% oxygen for 5 min in the microfluidic chamber [106]. GCaMP5K 
fluorescence was recorded by stream acquisition for 2 min at a rate of 8.34 
frames/second, with an exposure time of 20ms using a 12-bit Hamamatsu ORCA-ER 
digital camera. Each animal was recorded once, and GCaMP5K-expressing neurons 
were marked by a region of interest (ROI). The change in fluorescent intensity as per 
neuronal excitation and position of the ROI was tracked using the “Track Objects” function 
in MetaMorphTM. To subtract background from the total integrated fluorescence intensity 
of the ROI, an adjacent ROI was selected in the same image. MATLAB (MathWorks,Inc.) 
was used to analyze the data. Fluorescence intensity is presented as the percent change 
in fluorescence relative to the baseline (ΔF/F0). F0 was measured in worms exposed to 
10% oxygen during the first 9-13 seconds for each recording and calculated as an 
average over that period. The number of animals used for each condition is denoted in 
the figures. 
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Statistics 
Graphpad Prism 8.0 software package was used to calculate all p-values unless 
otherwise specified. Where only 2 conditions were compared, a two-tailed students t-test 
was performed. ANOVAs with appropriate post-test corrections were used when 
comparing multiple conditions.  
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Figure 2.1. acox-1 mutants are insensitive to the feeding stimulatory effects of 
serotonin  
(A) acox-1(ok2257) mutants are resistant to pharyngeal pumping increasing effects of 5mM 
serotonin.  All feeding data is expressed as a percentage of vehicle treated wildtype 
animals.  (B) Loss of acox-1 suppresses the elevated feeding rates of aak-2 animals. In 
both (A) and (B) error bars indicate +/- SEM from mean, n = 50 animals per strain. *** p < 
0.0001 ANOVA (Tukey) (C - D) acox-1 mutants accumulate significantly more fat than 
wildtype animals as assessed by hypodermal (green arrows) and intestinal (orange 
arrows) BODIPY fluorescence levels. Representative images of BODIPY staining (C) 
and corresponding quantifications of hypodermal BODIPY fluorescence levels (D) *** 
p<0.001, students t-test. (E) Fasting acox-1 mutants for 90 minutes restores their ability 
to elevate feeding in response to 5mM serotonin. Day 1 adult animals were either fed ad-
libitum or fasted for 90 minutes than plated on vehicle or 5mM 5HT plates for 60 minutes 
before assessing pharyngeal pumping rates. Error bars indicate +/- SEM from mean, n = 15 
animals per condition. ** p < 0.01 , *** p < 0.001 ANOVA (Tukey).  
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Figure 2.2 Reconstitution of acox-1 in the intestine rescues fat and feeding 
phenotypes 
(A) acox-1 is expressed in hypodermal (white arrows) and intestinal (orange arrow) 
tissues. Merged DIC and green epifluorescent image of a transgenic animal expressing a 
acox-1p::gfp transcriptional reporter. (B-C) Reconstitution of acox-1 gDNA under its own 
promoter (Pacox-1) and under an intestine specific promoter (Pvha-6) but not under a 
hypodermal-specific promoter (Pdpy-7) normalizes BODIPY fat levels. Representative 
images of BODIPY staining (B) and corresponding quantifications (C) expressed as 
fluorescence intensity relative to wildtype animals. The yellow arrow in (B) indicates a 
coelomocyte co-injection marker used during transgenic strain generation. Error bars 
indicate +/- SEM from mean, n>20 per strain.   *p<0.05, ***p<0.001, ANOVA (Tukey) (D) 
Reconstitution of acox-1 gDNA under an intestine specific promoter (Pvha-6) restores 
serotonin responsiveness. Relative pharyngeal pumping rates of indicated strains. Error 
bars indicate +/- SEM from mean, n > 15 per strain.  ***p<0.001, ANOVA (Tukey).  
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Figure 2.3 Modulation of feeding by ACOX-1 requires fatty acyl-CoA synthesis  
 (A) Inhibiting acyl-CoA synthesis (ACS) in acox-1(ok2257) animals restores the ability 
to elevate feeding in response to 5mM serotonin. Day 1 adult animals were pre-treated 
with vehicle or 1µM ACS inhibitor Triacsin C for 90 minutes before being plated on 
vehicle or 5mM 5HT plates. Feeding was assayed after 60 minutes on assay plates. 
Error bars indicate +/- SEM from mean, n = 15 animals per condition. ** p < 0.01 , *** p 
< 0.001 ANOVA (Tukey). (B) Animals were treated with 1mM oleic acid (OA) or 1µM 
Triacsin C (TC) for one hour, or pre-treated with 1µM TC or one hour prior to OA 
treatment before feeding was assayed.  Error bars indicate +/- SEM from mean, n > 15 
per strain.  ***p<0.001, ANOVA (Tukey) (C) Acyl-CoA levels in acox-1 mutants are 
unchanged relative to WT. Acyl-CoA species were separated and quantified by HPLC 
and normalized to protein concentrations, n = 3 independent extractions.  
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Table 2.1: Loss of acox-1 results in modest transcriptional changes in intestinal and 
fatty acid metabolic pathways  
 
** indicates intestinally expressed gene products  
WormBase ID Gene Name log2(FC) Cellular Process Putative Function P-value Adjusted p-value
UPREGULATED
WBGene00008681 scrm-4** 2.50 membrane phospholipids phospholid scramblase 7.83E-11 1.48E-06
WBGene00019404 K05B2.4** 1.98 peroxisomal fatty acid metabolism  
ortholog of human bile acid-CoA: amino acid 
N-acyltransferase (BAAT) 1.18E-04 8.71E-02
WBGene00013540 Y75B8A.3 1.89 fatty acid metabolism carboxylic ester hydrolase type B 1.83E-04 1.15E-01
DOWNREGULATED
WBGene00011487 T05E12.6** -1.64 unknown unknown 5.88E-05 5.83E-02
WBGene00019619 asp-14** -1.97 innate immune response aspartic endopeptidase 3.93E-05 5.54E-02
WBGene00007875 dod-24** -2.09 innate immune response unknown 2.33E-05 3.98E-02
WBGene00009429 irg-5 -2.10 innate immune response unknown 4.51E-05 5.54E-02
WBGene00009773 lipl-2** -2.15 fatty acid metabolism ortholog of human triglyceride Lipase F 2.67E-04 1.36E-01
WBGene00012671 Y39B6A.9 -2.17 unknown unknown 2.24E-04 1.17E-01
WBGene00019368 K03H6.2** -2.18 fatty acid metabolism putative lipase 2.18E-04 1.17E-01
WBGene00001150 ech-1.1** -2.18 fatty acid metabolism enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase activity 9.90E-05 8.24E-02
WBGene00014562 Y17D7B.7 -2.24 unknown unknown 4.67E-05 5.54E-02
WBGene00019495 sdz-24 -2.28 larval development SKN-1 dependent zygotic transcript 1.96E-04 1.15E-01
WBGene00007331 pho-11 -2.29 metabolic process ortholog of human acid phosphatase 2 7.81E-06 1.47E-02
WBGene00020560 T19C3.2 -2.29 unknown unknown 1.25E-04 8.75E-02
WBGene00007916 C34C6.3 -2.30 unknown unknown, contains an EGF-like domain 1.90E-04 1.15E-01
WBGene00006636 tsp-10** -2.30 unknown putative tetraspanin 5.29E-05 5.54E-02
WBGene00194708 Y36E3A.2 -2.31 membrane biology unknown 1.20E-04 8.71E-02
WBGene00008584 irg-4 -2.32 innate immune response unknown 2.23E-06 7.00E-03
WBGene00000747 col-174 -2.43 structural protein/collagen collagen 1.04E-04 8.24E-02
WBGene00021337 Y34F4.2** -2.47 membrane biology putative tight-junction/claudin 7.44E-05 7.01E-02
WBGene00008565 acox-2** -2.48 peroxisomal fatty acid metabolism  acyl-CoA oxidase 2.64E-06 7.11E-03
WBGene00009904 F49E12.12 -2.51 GPI anchor maturation PGAP2 ortholog 5.07E-05 5.54E-02
WBGene00022375 Y94H6A.2 -2.56 unknown unknown 2.22E-04 1.17E-01
WBGene00008905 F17B5.1 -2.61 redox biology putative thioredoxin 1.47E-04 9.53E-02
WBGene00022730 ZK402.3 -2.64 unknown unknown, contains a SPK domain 4.80E-05 5.54E-02
WBGene00020083 R57.2** -2.65 unknown unknown 1.44E-04 9.53E-02
WBGene00011665 T09F5.1 -2.66 protein glycosylation putative galactosyltransferase 9.29E-05 8.24E-02
WBGene00008564 acox-1** -2.74 peroxisomal fatty acid metabolism  acyl-CoA oxidase 2.01E-09 1.26E-05
WBGene00008698 F11D11.3** -2.76 innate immune response putative transmembrane glycoprotein 2.03E-04 1.16E-01
WBGene00022731 ZK402.5 -2.86 unknown unknown, contains a SPK domain 1.05E-04 8.24E-02
WBGene00022156 Y71G12B.18** -2.92 unknown unknown 6.98E-06 1.46E-02
WBGene00015268 BE0003N10.3 -2.93 zinc ion binding unknown 2.78E-07 1.31E-03
WBGene00010102 F55C9.5** -3.05 unknown unknown 3.07E-05 4.82E-02
WBGene00017020 D1014.7 -3.26 unknown unknown 1.27E-06 4.79E-03
WBGene00017019 D1014.6 -4.17 protein glycosylation unknown, putative galactosyltransferase activity 2.57E-10 2.42E-06
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Figure 2.4 Loss of acox-1 results large-scale changes to the global metabolome  
Venn diagrams showing total numbers of detected features (6408 and 3604) and 
numbers of metabolites more than three-fold upregulated (pink) or downregulated (blue) 
in LC-HRMS using positive-ion (ESI+) and negative-ion (ESI-) electrospray ionization in 
acox-1 mutants. Though most differentially detected features were unidentifiable, the 
chemical structures shown here represent examples of the most significantly up or 
down regulated compounds in identifiable metabolic classes.  See Supplemental Table 
1. 
 
 
 93 
 
 
 
 
 
 
 
A
WT
acox-1
B
WT acox-1
0
20
40
60
80
# 
eg
gs
 re
ta
in
ed
 in
 u
te
ro
 p
er
 a
ni
m
al
***
W
T
ac
ox
-1
ac
ox
-1;
 P
ac
ox
-1:
:(+
)
ac
ox
-1;
 P
vh
a-6
::(+
)
ac
ox
-1;
 P
dp
y-7
(+)
0
10
20
30
40
50
60
# 
eg
gs
 re
ta
in
ed
 in
 u
te
ro
 p
er
 a
ni
m
al
******
F G
C
Figure 5
D E
WT acox-1
0
5
10
15
20
# 
eg
gs
 la
id
 in
 liq
ui
d
M9
M9 +           
5 mg/mL 
5HT   
***
W
T
ac
ox
-1
ac
ox
-1;
eg
l-2
(lf)
0
15
30
45
60
# 
eg
gs
 re
ta
in
ed
 in
 u
te
ro
 p
er
 a
ni
m
al
******
WT
acox-1
acox-1; Pacox-1::(+)
acox-1; Pvha-6::(+)
acox-1; Pdpy-7::(+)
WT
acox-1
acox-1;egl-2(lf)
 94 
Figure 2.5 acox-1 mutants exhibit egg-laying defects 
(A-B) acox-1(ok2257) mutants accumulate significantly more eggs in utero than wildtype 
animals. Representative DIC images (A) and quantification (B) of eggs retained in utero. 
Error bars indicate +/- SEM from mean, n = 30 animals per genotype. *** p < 0.001 
unpaired student’s t-test. (C) acox-1 animals are less responsive to the egg-laying inducing 
effects of serotonin. Egg-laying response of wildtype and acox-1 in control buffer (M9) or 
5mg/mL serotonin in M9 buffer. Data represents the number of eggs released per animal 
after a 20-minute exposure to vehicle or drug. Error bars represent +/- SEM from mean. n = 
20 animals per condition,  *** p < 0.001 ANOVA (Sidak) (D-E) Reconstitution of acox-1 
gDNA under an intestine specific promoter (Pvha-6) but not a hypodermal specific promoter 
(Pdpy-7) restores egg-laying capacity to acox-1 mutants. Representative DIC images (D) 
and quantification (E) of eggs retained in utero. Error bars indicate +/- SEM from mean, n = 
30 animals per genotype, *** p < 0.001 unpaired student’s t-test, against a wildtype control. 
(F-G) Loss of egl-2 rescues acox-1 egg-laying defects. Representative DIC images of 
each genotype (F) and quantification (G) of eggs retained in utero. Error bars indicate +/- 
SEM from mean, n = 30 animals per genotype. *** p < 0.001 unpaired student’s t-test.  
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Figure 2.6. ACOX-1-mediated regulation of serotonergic feeding responses 
requires the EGL-2 K+ channels  
(A) Pharyngeal pumping rates of wildtype, egl-2(n698), and egl-2 RNAi treated egl-2(n698) 
mutants on vehicle or 5mM 5HT containing plates. (B) Pharyngeal pumping rates of 
wildtype and acox-1(ok2257) animals treated with vector RNAi or egl-2 RNAi and vehicle or 
5mM 5HT (C) Pharyngeal pumping rates of indicated strains treated with vehicle or 5mM 
5HT.   Error bars indicate +/- SEM from mean, n=20 animals per condition. *p<0.05, *** p < 
0.001,  ANOVA (Tukey) (D) EGL-2 is required for animals to reduce feeding in response to 
oleic acid. Animals were exposed to 1mM Oleic Acid for one hour before feeding was 
assayed.   n> 15 per strain, Error bars indicate +/- SEM from mean,   ***p<0.001, ANOVA 
(Tukey). All feeding data are expressed as a percentage of vehicle treated wildtype 
animals. 
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Figure 2.7. Body cavity neurons modulate feeding behavior  
(A) EGL-2 is expressed in a limited subset of sensory neurons. Epifluorescent image of a 
transgenic animal expressing egl-2p::gfp transcriptional reporter. Yellow and green arrows 
indicate the AQR and URX body cavity neurons, respectively. (B) Animals expressing egl-
2(gf) in body cavity neurons do not elevate feeding in response to 5mM 5HT. Pharyngeal 
pumping rates of wildtype and pgcy-32::egl-2(gf) expressing animals treated vehicle or 
5mM 5HT. (C) Constitutive activation of synaptic release from body cavity neurons 
stimulates feeding.  Pharyngeal pumping rates of wildtype, acox-1(ok2257), CX10386 
pgcy-32::pkc-1(gf) and acox-1; CX10386 pgcy-32::pkc-1(gf) animals on vehicle or 5mM 5-
HT. In (B) and (C) data are expressed as a percentage of vehicle treated wildtype animals. 
Error bars indicate +/- SEM from mean, n=15 animals per condition.  *** p < 0.001 two way 
ANOVA (Tukey). 
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Figure 2.8 Loss of acox-1 suppresses URX body cavity neuron activity  
(A-D) Activity of URX neurons in each indicated genotype using Ca2+ imaging by 
GCaMP5K under the control of the URX specific flp-8 promoter. Oxygen concentrations 
in the microfluidic chamber were 10% and 21% as indicated. (A-B) For each genotype, 
black traces show the average percent change of GCaMP5k fluorescence (F∆/F0) and 
gray shading indicates SEM. The number of animals used for each condition is shown 
in the figure.  (C-D) Individual URX responses are shown for each genotype; each row 
represents one animal. (E) Maximal (F∆/F0) values are shown for individual animals in 
wildtype and acox-1 animals. Bars indicate the average value within each genotype. 
***p<0.001 by students t-test. (F) Individual baseline fluorescence (F0) values at 10% 
oxygen are shown for individual animals in wildtype and acox-1 mutants. Bars indicate 
the median value within each genotype; n.s., not significant by students t-test (G) We 
imaged mCherry fluorescence in wildtype and acox-1 mutant animals expressing both 
GCaMP5K and mCherry under the control of the flp-8 promoter. Images were taken in 
animals exposed to 10% oxygen. For each genotype, the fluorescence intensity was 
imaged at the same exposure, determined to be within the linear range. Fluorescence 
intensity was quantified and is expressed as the mean +/- SEM (n = 23). n.s., not 
significant by students t-test.  
 
 
 
 99 
 
 
 
Figure 2.S1, related to Figure 2.1 
(A) Knocking down acox-1(F08A8.1) by RNAi suppresses the feeding elevating effects 
of exogenous serotonin (5mM 5HT).  Animals were treated with RNAi from L1 stage and 
feeding was assayed at day 1 adult stage.  Feeding data is expressed as a percentage 
of vehicle treated wildtype animals. Error bars indicate +/- SEM from mean, n = 20 
animals per strain. *** p < 0.001 ANOVA (Tukey)  (B) Loss of acox-1 does not influence 
the transcriptional expression of tryptophan hydroxylase (tph-1) as measured by qPCR. 
Error bars indicate +/- SEM from mean n = 3 independent assays (C) Relative 
abundance of 5-HT in wildtype and acox-1 mutants, as determined by LC-HRMS. Error 
bars indicate +/- SEM from mean, n = 4 independent experiments. (D) Loss of acox-1 
does not grossly alter amphid neuron morphology. DiI staining of amphid chemosensory 
neurons in wildtype and acox-1 mutants. Images acquired at day 1 adult stage.  
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Figure 2.S2, related to Figure 2.3  
(A) RNAi-mediated inactivation of distinct acyl-CoA synthases suppress feeding defects 
in acox-1(ok2257) animals. Animals were treated with respective RNAi clones from L1 
stage and feeding was assayed at day 1 adult stage. Feeding data is expressed as a 
percentage of vehicle treated wildtype animals. Error bars indicate +/- SEM from mean, 
n = 15 animals per strain. *<0.05, *** p < 0.001 two way ANOVA (Tukey).  
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Figure 2.S3, related to Figure 2.4  
(A) daf-22(ok693) animals are still responsive to the feeding elevating effects of 5mM 
serotonin. n=10 animals per condition (B) Feeding responses of wildtype animals to 
ascaroside #18 (ascr #18). Animals were exposed to 1µM and 5µM ascr#18 from L1 
stage and pharyngeal pumping rates were determined at day 1 adult stage. n = 15 
animals per condition (C) Feeding responses of wildtype animals to thiamine. Animals 
were exposed to 0.5 µg/µL thiamine and 1.0 µg/µL thiamine from L1 stage and 
pharyngeal pumping rates were determined at day 1 adult stage. n = 15 animals per 
condition (D) RNAi-mediated inactivation of fatty acid amide hydrolase (faah-1) elevates 
feeding responses of wildtype and acox-1 mutants. Animals were grown on faah-1 RNAi 
from L1 stage and feeding was assayed at day 1 adult stage. n = 10 animals per 
condition.  All feeding data is expressed as a percentage of vehicle or vector treated 
wildtype animals. Error bars indicate +/- SEM from mean, *** p < 0.001 two way ANOVA 
(Tukey).  
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Figure 2.S4, related to Figure 2.5  
(A) acox-1(ok2257) mutants lay eggs at a later developmental stage that wildtype 
animals, suggesting that in utero retention time is increased.  Histograms indicate the 
distribution of embryos at each developmental stage. (B) acox-1 mutants are less 
responsive to the egg-laying inducing effects of serotonin. Egg-laying response of 
wildtype and acox-1 mutants in control buffer (M9) or 0.5mg/mL fluoxetine. Data 
represents the number of eggs released per animal after a 20-minute exposure to 
vehicle or drug. Error bars represent +/- SEM from mean. n = 15 animals per condition,  
*** p < 0.001 ANOVA (Sidak) (C-D) Inactivation of egl-2 via RNAi rescues acox-1 egg-
laying defects. Representative DIC images of day 1 adults of each genotype (C) and 
quantification (D) of eggs retained in utero. Error bars indicate +/- SEM from mean, n = 
15 animals per genotype. *** p < 0.001 unpaired student’s t-test. 
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Figure 2.S5, related to Figure 2.6(A) RNAi-mediated knockdown of egl-2 rescues egg-
laying defects associated with aberrant channel activity egl-2(n698) mutants. 
Representative DIC images acquired from day 1 adults.  
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Figure 2.S6.  Effects of Triacsin C on URX body cavity neuron activity  
(A-H) Activity of URX neurons in each indicated genotype and treatment using Ca2+ 
imaging by GCaMP5K under the control of the URX specific flp-8 promoter. Oxygen 
concentrations in the microfluidic chamber were 10% and 21% as indicated. (A-D) For 
each genotype and treatment group, black traces show the average percent change of 
GCaMP5k fluorescence (F∆/F0) and gray shading indicates SEM. The number of 
animals used for each condition is shown in the figure.  (C-D) Individual URX responses 
are shown for each genotype and treatment; each row represents one animal. (I) 
Maximal (F∆/F0) values are shown for individual animals in wildtype and acox-1 animals 
+/- Triacsin C. Bars indicate the average value within each genotype. ***p<0.001 by 
students t-test. (J) Individual baseline fluorescence (F0) values at 10% oxygen are 
shown for individual animals in wildtype and acox-1 mutants. Bars indicate the median 
value within each genotype; n.s., not significant by students t-test (K) We imaged 
mCherry fluorescence in wildtype and acox-1 mutant animals expressing both 
GCaMP5K and mCherry under the control of the flp-8 promoter. Images were taken in 
animals exposed to 10% oxygen. For each genotype, the fluorescence intensity was 
imaged at the same exposure, determined to be within the linear range. Fluorescence 
intensity was quantified and is expressed as the mean. (L) The background-subtracted 
maximum fluorescence (max FL) at 21% (high) oxygen is shown for each genotype and 
treatment group. Bars indicate the median value within each genotype or treatment 
group. +/- SEM (n = 23). n.s., not significant by students t-test.   
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Chapter III: CPT-6 is expressed in the nervous system and 
regulates social feeding behavior 
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Introduction 
We previously reported that RNAi inhibition of either F08A8.1/acox-1 and 
W01A11.5/cpt-6 suppress the feeding increasing effects of serotonin. cpt-6 encodes an 
orthlogue of mammalian carnitine palmitoyl transferase I (CPT1), an enzyme that 
catalyzes the conversion of long chain fatty acyl-CoAs to fatty acyl-carnitines for 
translocation across the outer mitochondrial membrane. Like ACOX-1 in peroxisomal fatty 
acid oxidation, CPT-6 is hypothesized to control the rate of flux of cytosolic fatty acyl-
CoAs into the mitochondrial matrix and thus function as a gate-keeper of mitochondrial 
fatty acid oxidation [37]. As loss of either CPT-6 and ACOX-1 abrogates the increased 
feeding rate of serotonin treated animals, we hypothesized that an accumulation of fatty 
acyl-CoAs, the metabolic substrates of these enzymes initiates an anorexigenic 
response. In mammals, pharmacologic manipulations that increase levels of 
hypothalamic fatty acyl-CoAs also inhibit feeding suggesting these moieties may play a 
conserved role in feeding regulatory circuits[112].  
Though ACOX-1 has not previously been implicated in mammalian feeding 
regulation, a growing body of literature implicates mammalian carnitine palmitoyl 
transferase in the hypothalamic control of feeding. In particular, CPT1c, a brain specific 
isoform of the enzyme has emerged as key regulator of organismal energy 
homeostasis[146]. Mice lacking CPT1c have reduced food intake and body fat than their 
wildtype counterparts yet paradoxically, these animals are more susceptible to obesity 
when fed a high-fat diet[146]. This is hypothesized to be due in part due to disruption of 
hypothalamic leptin and ghrelin signaling pathways. Specifically, CPT1c KO animals are 
resistant to the anorectic effects of leptin and ghrelin [147,148]. In addition, a recent study 
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suggests that CPT1c activity in the mediobasal hypothalamus is required for the induction 
of brown adipose tissue thermogenesis by leptin [149].  
CPT1c has a shares a high degree of homology with CPT1a and CPT1b, the liver 
and muscle specific isoforms of the enzyme. Though all three isoforms share the capacity 
to bind fatty acyl-CoAs, CPT1c curiously lacks capacity to transfer fatty acyls to carnitine 
and is expressed uniquely in the endoplasmic reticulum (ER) suggesting it may play a 
non-canonical role in lipid metabolism [146] [150]. Metabolomic profiling of CPT1c KO 
mice confirms the notion that this isoform plays a limited role in mitochondrial fatty acid 
oxidation as no changes in metabolites associated with fatty acid oxidation were detected. 
Loss of CPT1c does significantly reduce the levels of certain fatty acyl ethanolamines and 
increase ceramide production [151]. These two lipid families have well established roles 
in the regulation of feeding and have been proposed as potential downstream effectors 
of CPT1c [147].  
Despite a clear role for CPT1 in the regulation of feeding, the precise role of this 
enzyme in the nervous system remains unclear. Moreover, though this enzyme has been 
shown to mediate the effects of peripherally derived endocrine signals (i.e ghrelin, leptin), 
no studies have examined the influence of CPT1 on neuroendocrine circuits that regulate 
feeding behavior. Our data suggests that CPT1 enzymes may exert their effects on 
feeding by modulating serotonergic signaling circuits.  
Here, we describe the generation and preliminary phenotypic analysis of a novel 
allele of cpt-6, an ortholog of mammalian CPT-1. We find that CPT-6 is expressed broadly 
within the C. elegans nervous system and may play a role regulating pharyngeal pumping 
and social feeding behaviors.   
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Results 
We previously reported that RNAi inhibition of W01A11.5/cpt-6 suppress both the 
fat reducing and feeding increasing effects of serotonin. To investigate how loss of cpt-6 
influences serotonin signaling, we utilized CRISPR/Cas9-directed genome editing to 
generate cpt-6 mutants as no genetic mutants for this gene currently exist. Using a dual 
sgRNA-directed strategy with non-homologous end joining dependent repair, we generated 
a novel deletion allele of cpt-6 [152]. Guide RNAs were designed to target PAM sites that 
flank the first exon and a portion of the second exon resulting in a ~397bp deletion (Figure 
1A-D).   
The developmental timing, size and health of the resulting cpt-6 mutants appear 
grossly wildtype. cpt-6 mutants however have reduced rates of pharyngeal pumping and are 
partially unresponsive to the feeding increasing effects of serotonin (Figure 2A). In addition 
to the noted feeding defects, cpt-6 mutants exhibit a preference for low oxygen regions at the 
border of bacterial lawns and demonstrate a social feeding behavior. To examine the 
expression pattern of CPT-6, we generated a translation reporter consisting of a full length 
cpt-6 cDNA fused to a C-terminal GFP under the control of the endogenous cpt-6 promoter. 
CPT-6 is expressed broadly within the nervous system with notable expression in the ventral 
cord motor neurons and over 50 distinct head neurons. Slight expression was also noted in 
the intestine and vulva. Closer examination, particularly with co-injection markers illuminating 
known neurons, will be required to more specifically identify the neurons in which CPT-6 is 
expressed.  
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Discussion 
 We have generated a novel deletion allele of W01A11.5/cpt-6 using CRISPR/Cas9 
editing. This deletion removes ~400bp region of the gene that represents the first 
exononic region and the beginning portion the second.  This mutation is presumed a null 
given the large deletion, however we cannot entirely rule out the possibility that a 
downstream ORF gives rise to a partially functional gene product. The feeding phenotype 
of this novel mutant recapitulated the result attained with RNAi knockdown against CPT-
6 supporting the notion that this mutation results in a loss of CPT-6 function.  
 CPT-6 is predominantly expressed in the C. elegans nervous system though the 
specific neurons or neuronal subtypes remain unknown. This result was unexpected 
given the previously held notion that this protein was uniquely expressed in peripheral 
tissues. In mammals, it is the neuronal function of CPT-1c that is largely thought to 
contribute to the regulation of whole energy homeostasis. It is possible that CPT-6 plays 
a similar enzymatic and mechanistic function in C. elegans neurons. To further explore 
this possibility it will be interesting to examine the localization patterns of the remaining 5 
CPT-1 orthologs to determine if any CPTs are expressed within the nervous system.  
Importantly, it will be important to determine the subcellular localization of CPT-6 as the 
feeding regulatory effects of CPT-1c stem from its function in the endoplasmic reticulum 
rather than the canonical mitochondrial role. Preliminary metabolomic analyses suggest 
that numerous metabolic and lipidomic species including phospholipids, ascarosides and 
short polypeptides are altered in cpt-6 mutants (Schroeder Data). Further biochemical 
analyses will be required to more specifically determine the nature of the metabolic 
changes arising in cpt-6 mutants.  
 111 
It is intriguing that loss of CPT-1c in mammals results in altered fatty acid 
ethanolamine synthesis as these species were also among the most differentially 
expressed in acox-1 null animals. Fatty acid ethanolamines may represent a common 
regulatory node in through which ACOX-1 and CPT-6 influence feeding behavior.  Closer 
examination of the role of fatty acid ethanolamines in regulating serotonergic circuits and 
feeding behavior should be prioritized.  
 The most notable phenotype exhibited by cpt-6 mutants is the bordering 
phenotypes. These mutants exhibit a preference for low oxygen environments,  a well-
studied behavior known to be under the control of the URX-RMG hub-and-spoke circuit 
[33,103,120,123]. This is particularly intriguing considering the purported role for URX 
body cavity in energy homeostasis and metabolic sensing as shown by our recent study 
and other groups [103,107,121,122].  It will be important to determine whether CPT-6 is 
expressed in URX, RMG or other body cavity neurons. Follow-up experiments could 
probe the role of URX or RMG neurons in regulating oxygen preferences in cpt-6 mutants 
by determining whether activation or ablation of these neurons rescues the bordering 
phenotype.  
cpt-6  and acox-1 were originally identified as suppressors of the feeding 
increasing effects of serotonin from the same experiment[19]. Interestingly, these two 
proteins are expressed in distinct tissues, acox-1 is only expressed with peripheral tissues 
whereas cpt-6 is predominantly expressed in the nervous system. In mammals, changes 
in lipid metabolism either in peripheral tissues or directly within feeding regulatory regions 
within the hypothalamus can influence feeding behavior and changes in hypothalamic 
lipid metabolism can influence distant peripheral metabolic circuits [10,12,112,146,153].  
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We have demonstrated that URX and oxygen sensing neurons play a key role in 
mediating the effects acox-1 on feeding behavior. It is therefore highly intriguing that loss 
of cpt-6 modulates social feeding behavior and normoxia avoidance as it suggests that 
URX neurons and oxygen sensing circuits may represent a common mechanism through 
which peripherally and neuronally derived lipid metabolic species influence the behaviors 
and physiologies that underlie energy homoeostasis.  
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W01A11.5
gRNA #1 gRNA #2
del
A
C
Primer ID Sequence Target Sequence Source
cpt-6 guide RNA PAM #1 cctcctattgcgagatgtcttgCGACATCTGAAATTATGGTAgtttaagagctatgctgg Targets: CGACATCTGAAATTATGGTA(AGG) in antisense From ChopChop
cpt-6 guide RNA PAM#3 cctcctattgcgagatgtcttgTGGGTATTTGTAGTGTAGGGgtttaagagctatgctgg Targets TGGGTATTTGTAGTGTAGGG (TGG) in antisense From crispr.mit.edu
genotyping forward cgctcattcaacaacacgga
genotyping reverse gaatgtttccagcttggcga
D
B
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 Figure 3.1 Generation of a novel allele of W01A11.5/cpt-6  
We have generated a novel allele of cpt-6 using CRiSPR/Cas9 (A) Map of the exonic and 
intronic regions of W01A11.5/cpt-6 with the location of the ~ 397bp deletion indicated in red 
brackets. (B) Alignment of DNA sequence of wild-type and the novel cpt-6 allele.  (C) Guide 
RNAs and sequencing primer sequences. Guide RNAs designed was aided with 
ChopChop or crispr.mit.edu software as indicated. (D) PCR confirmation of resulting 
deletion event. Expected wildtype product = 1695bp and mutant product = ~1300bp.  
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Figure 3.2 CPT-6 is expressed in the nervous system and plays a role in regulating 
feeding behavior and oxygen preference  
 (A) cpt-6 mutants have reduced feeding rates and are partially insensitive to the feeding 
increasing effects of serotonin. Feeding data is preliminary in nature and represents an 
n=10 animals. (B) Expression of a cpt-6p::cpt-6cDNA::GFP suggest that CPT-6 primarily 
functions in the nervous system (C) cpt-6 mutants exhibit social feeding behavior and a 
preference for low oxygen regions on the border E. coli source.  
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In this study, we uncover the architecture of a novel gut-to-brain regulatory axis 
that links peripheral metabolic information with neuroendocrine signaling circuits that 
regulate nutrient-related behaviors. This work offers mechanistic insight into how 
nutrient cues can modulate neuromodulatory circuits implicated in the control of mood, 
cognition and behaviors. Two areas of investigation should be prioritized in follow-up 
studies.  
1. Investigating the influence of body cavity neurons on serotonergic circuits 
We identified the body cavity neurons as a key link between peripheral metabolic 
cues and serotonergic signaling. We hypothesize that these neurons are capable of 
sensing numerous metabolic cues from the coelomic fluid and serve as an entry point 
into a circuit that links peripheral metabolic information with neuroendocrine circuits. 
However, it is still currently unclear what signals are released by URX neurons to 
regulate feeding (and potentially egg-laying) nor which cells are downstream recipient of 
these signals. Constitutive activation of synaptic vesicle and dense-core vesicle release 
from these neurons strongly stimulates feeding though intriguingly and somewhat 
perplexingly, genetic ablation of these neurons restore serotonin sensitivity to acox-1 
mutants (Figure 1). Taken together, these results paint a complicated role for body 
cavity neurons in this circuit as it seems that their activity is required to both suppress 
and activate feeding responses. Further investigation is required to more specifically 
determine the specific role and influence of body cavity neurons in the regulation of 
feeding behavior as it is possible that multiple signals are released from these neurons 
to control feeding. One area of investigation should focus on more specifically defining 
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contributions of AQR, PQR and URX neurons to feeding behavior. Given our GCaMP 
results, examining the contribution of URX neurons should be prioritized. Such an 
experiment would consist generating transgenic animals in which  egl-2(gf) and pkc-
1(gf) are expressed the URX specific flp-8 promoter and determining the effects of 
inhibition and activation of URX neurons on feeding behavior. We hypothesize that 
inhibition of URX neurons will suppress serotonergic responses while activation of these 
neurons will stimulate feeding.  
Next, it will be important to determine the nature of the signal(s) released from 
URX/body cavity neurons in the control of pharyngeal pumping. URX neurons are both 
cholinergic and peptidegic and specifically secrete a number FMRFamide-like peptides 
(flp), a family of neuropeptides involved in the control of most complex behaviors 
including feeding and egg-laying [83,154–156]. We showed that activation synaptic 
vesicle and dense core vesicle release stimulates feeding behavior suggesting that 
either a cholinergic or peptidergic signal from these neurons functions to enhance 
feeding responses. To resolve the role of neuropeptides specifically, an important 
experiment will be to selectively suppress dense-core vesicle release from URX 
neurons. RAB-5 is a Rab GTPase that is required for dense-core vesicle release but 
plays no role in synaptic vesicle release. It’s been previously shown that expression of a 
constitutively active version of this protein, rab-5(Q78L) blocks neuropeptide release in 
a cell-autonomous manner [157]. If neuropeptide release from URX neurons is required 
to stimulate feeding responses, we would expect an animal expressing the rab-5(Q78L) 
transgene under a flp-8 promoter to have blunted responses to exogenous serotonin in 
a manner that phenotypically recapitulates the responses of acox-1 mutants. If this is 
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the case, a screen for specific neuropeptides should be carried out perhaps utilizing a 
strain with RNAi sensitivity specifically in URX neurons.  If animals lacking peptidergic 
signaling from URX neurons still retain full responsiveness to serotonin, it could suggest 
that a cholinergic tone rather than a peptidergic signal from these neurons regulates 
feeding.  
There is some preliminary evidence that acetylcholine signaling is altered in 
acox-1 mutants.  Acetylcholine plays a key role in mediating excitatory neuromuscular 
responses and stimulates pharyngeal pumping [158–161]. Animals defective in 
acetylcholine synthesis or release have reduced feeding rates of pharyngeal pumping 
[162,163].  It has also been proposed that the experience of starvation modulates 
pharyngeal muscle excitability in turn influencing feeding behavior in a mechanism that 
involves the GAR-3 muscarinic cholinergic receptor [29]. A few pieces of data that 
suggest that altered acetylcholine signaling may contribute to the feeding and egg-
laying defects noted in acox-1 mutants. Both acox-1 and acox-1;aak-2 mutants are 
partially resistant to the paralyzing effects of the acetycholinerase inhibitor, aldicarb 
suggesting that acetylcholine release or transmission is reduced in these animals 
(Figure 2). Preliminary data from direct biochemical measurements of acetetylcholine 
and choline, the rate-limiting substrate in the synthesis of acetylcholine suggests that 
levels of this neurotransmitter in whole animal lysates are indeed reduced in acox-1 and 
cpt-6 mutants (Figure 3, Yan Yue, Schroeder Lab – communicated findings). As choline 
levels are unchanged in these animals, it remains possible that either the synthesis of 
acetylcholine is slowed by reduced levels or activity of choline acetyltransferase (ChAT) 
or the breakdown of acetylcholine is increased by higher levels or activity of 
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acetylcholine esterase, the enzyme involved in breakdown of acetylcholine. 
Reexamination of our RNAseq data suggest that a putative acetylcholine esterase 
(Y75B8A.3) is indeed 2.5 fold higher in acox-1 and aak-2;acox-1 mutants. This gene 
was not included in our screen of RNAseq hits, and it will be interesting to determine if 
contributes to the behavioral responses of acox-1 mutants. If reduced cholinergic 
signaling leads to reduced excitability of serotonergic responses, inactivation or knock-
down of acetylcholine esterase levels would be hypothesized to rescue the noted 
behavioral phenotypes of acox-1 mutants.  
Acetylcholine signals through two broad families of receptors, the 
metabotropic/G-protein coupled muscarinic receptors (mAChRs) and the ionotropic 
nicotinic receptors (nAChRs) [164]. To begin exploring the influence of cholinergic 
signaling on feeding, we first explored the influence of muscarinic acetylcholine 
signaling on feeding responses. Transient treatment with atropine, a muscarinic 
receptor antagonist suppresses the pharyngeal pumping rates of both wildtype and aak-
2 mutants (Figure 3A). Conversely, treatment with arecoline, a muscarinic receptor 
agonist did not restore high feeding rates to aak-2;acox-1 (Figure 3B). These 
preliminary experiments suggest that muscarinic signaling is required for serotonin-
mediated feeding increases, but not sufficient to stimulate feeding or to rescue the 
suppression induced by loss of ACOX-1. As both muscarinic and nicotinic acetylcholine 
signaling have been shown to regulate serotonin responses in both the pharyngeal and 
vulval neuromuscular,  a follow-up set of experiments could explore the role of nicotinic 
cholinergic signaling [165–167]. It is well established that animals lacking EAT-2, a 
nicotinic cholinergic receptor, have reduced feeding responses [159,167]. The roles of 
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nicotine or other nicotinic cholinergic receptor agonists on C. elegans behaviors are less 
well defined. Transient exposure to nicotine has been shown to stimulate egg-laying 
behavior and excite dissected pharyngeal muscles [167,168]. If reduced nicotinic 
signaling contributes to the suppression of serotonergic feeding responses in acox-1 
mutants, nicotine supplementation may rescue feeding and egg-laying defects. If this is 
the case, the role and site of action of specific nicotinic acetylcholine receptors 
(nACrRs) should be probed. Such experiments could help elucidate mechanistic and 
cellular components that lie downstream of URX and body cavity neurons in the 
regulation of feeding and egg-laying behavior.  
2. Characterizing the role of N-acylethanolamines in regulating feeding behavior  
Our metabolomic analyses suggest that the synthesis of fatty acyl ethanolamine 
synthesis may be altered in acox-1 mutants. Metabolic intermediates in the biosynthesis 
of N-acylethanolamines were among the most significantly altered. N-
acylethanolamines, endogenous ligands of cannabinoid receptors, are potent 
neuromodulators and regulate numerous behaviors and physiologies including appetite, 
lifespan, mood and cognition [79,115–118].  We find that inactivation of fatty acid amide 
hydrolase (faah-1), an enzyme involved in the hydrolytic degradation of NAEs, 
stimulates both feeding and egg-laying responses in wildtype, acox-1, aak-2;acox-1 
mutants (Figure S4D-1, Figure 4A). To place FAAH-1 within an existing feeding 
regulatory framework, we performed an epistasis analysis with known components of 
serotonergic feeding circuits. Animals deficient in serotonin due to a mutation in tph-1 
fail to increase pharyngeal pumping rates on faah-1 RNAi (Figure 4B). This suggest that 
the effects of NAEs on feeding behavior require serotonin signaling.  
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NAEs are synthesized by N-acyl phosphatidylethanolamine phospholipase D (nape-
1), an enzyme that hydrolyses N-acylphosphatidyethanolamines to produce N-
acylethanolamines and phosphatidic acid. RNAi inactivation of nape-1 generates an 
“anxiety-like” phenotype where animals exhibit extremely rapid bouts of feeding after 
mechano-stimulation (ex. movement of plates) before eventually stabilizing back to 
wildtype levels (data not shown). This curious phenotype merits closer investigation and 
may suggest that NAPE-1 and NAE products play roles in gating the excitability of 
sensory circuits.   
How might NAEs regulate feeding and egg-laying behavior and sensory 
responsiveness? Endocannabinoids are potent neuromodulators and play a key role in 
regulating neuronal excitability in part due to their actions on serotonergic systems 
[169]. Indeed, there is high degree of overlap in the behaviors and physiologies 
regulated by endocannabinoid and serotonergic signaling and cannabinoid-driven 
effects often require the involvement of serotonergic signals [79,118,169]. 
Endocannabinoids have been shown to modulate the release of serotonin, alter the 
expression and activity of serotonin and influence the excitability of serotonergic 
neurons [170,171]. In mammals, most of these effects require the activity of the 
canonical Gαo- coupled cannabinoid receptors, CB1 and CB2 [172].   
Though C. elegans synthesize endocannabinoids, they were long thought to lack 
clear orthologs for mammalian CB1 and CB2 receptors [173–175]. However, a recent 
report suggests that the neuropeptide receptor npr-19 binds at least two major 
endocannabinoids 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide 
(AEA) and functions as a cannabinoid receptor [176]. Intriguingly, npr-19 is expressed in 
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a limited subset of neurons including the URX body cavity neuron and the M3 
pharyngeal motoneuron where it mediates the effect of 2-AG and AEA on numerous 
behaviors, including feeding, nociception and locomotion. It is highly intriguing that npr-
19 is expressed in the URX body cavity neurons as it suggests that it may play a role in 
mediating the effects of loss of ACOX-1 on feeding. Cannabinoids are known to have 
state-dependent and counterbalancing effects. If cannabinoid signaling through NPR-19 
is required to block feeding increasing effects of serotonin, we would expect an acox-
1;npr-19 animals to have wildtype feeding responses. Alternatively, certain cannabinoid 
species may stimulate feeding through NPR-19 in which case, it is possible that npr-19 
mutants resemble acox-1 mutants and fail to respond to serotonin.  It will also be 
important to determine if npr-19 is required for the feeding increasing effects of faah-1 
RNAi or the regulation of URX neuron activity. 
 NPR-19 long evaded BLAST searches for cannabinoid receptors as it only shares 
23% homology with human CB1. There are still numerous orphaned neuropeptide 
receptors that may play a role in mediating the effects of cannabinoids in C. elegans. It 
is also possible that npr-19 or other NPR/CB-like receptors play no role in mediating the 
effects of ACOX-1 or FAAH-1 on feeding. Indeed it has been established in mammalian 
systems that not all not  fatty acylethanolamines bind or activate cannabinoid receptors 
though the mechanisms of action for the receptor-inactive acylethanolamines remain 
poorly understood [177]. Given the lack of clear CB homologs, C. elegans are likely an 
excellent model to identify novel and perhaps more evolutionarily ancient mechanisms 
that underlie the influence of cannabinoids and fatty acylethanolamines on behavior and 
physiology.  
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Lastly, the contribution of individual N-acylethanolamines and their precursors in 
the regulation of feeding should be examined. We conducted a preliminary 
supplementation analysis and found that addition of docosahexaenoic acid (DHA), 
docosahexaenoylehanolamine (DHEA) and arachidonic acid (AA)  stimulate feeding in 
wildtype animals while DHA, DHEA and the eicosapentaenoic acid (EPA) derivative  
eicosapentaenoic ethanolamine (EPEA) elevate feeding rates in acox-1 mutants (Figure 
6). DHA, AA and EPA  are major components of neuronal phospholipids and play 
significant and conserved roles in the development and function of the nervous system. 
Though our screen was limited, it is notable that the only fatty acid “hits” (AA, EPEA, DHA 
and DHEA) belong or are derived to the omega-3 and omega-6 family of fatty acids. There 
is an overwhelming amount of literature highlighting the protective role of these lipids on 
the incidence and severity of wide range of psychiatric, neurological and 
neurodegenerative conditions through their precise contribution to neuronal and cognitive 
health remain unclear. Some of these protective influences of omega-3/6 fatty acids are 
hypothesized to require the conversion of these lipids to their cognate N-acyl 
ethanolamines [178–180].   
Despite the physiologically essential role of omega 3 fatty acids, virtually all 
vertebrate species are incapable of catalyzing the sequential desaturation reactions 
required to synthesize these lipids de novo. Instead, these lipids must be acquired from 
dietary sources or synthesized from the essential fatty acid precursor, α-linoleic acid 
(ALA, 18:3n-3). In vertebrates, ALA is progressively desaturated and elongated to 
tetracosapentaenoic acid (24:6n-3) in the endoplasmic reticulum. Tetracosahexaenoic 
acid is subsequently translocated to the peroxisomal matrix where it is shortened to DHA 
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in part through the action of ACOX-1 [181].  Unlike mammals, C. elegans and other 
nematodes seem to have the capacity to generate DHA de novo though it is unclear how 
much is generated via a de novo pathway versus the ACOX-1 and ALA dependent circuit 
[182,183]. It will be important to re-mine the metabolomics data to determine if acox-1 
mutants have altered levels of DHA, EPA and other related polyunsaturated fatty acid 
derivatives (i.e fatty acyl ethanolamines). It is hypothesized that the ratio of omega-3 to 
omega-6 fatty acids contributes to pathogenic or dysfunctional states so it will be 
important to access both absolute and relative levels of these lipids in acox-1 mutants 
[184]. As polyunsaturated fatty acids are major structural components of cellular 
membranes and functional modulators of cellular function these preliminary data are 
highly intriguing. Long chain poly/unsaturated fatty acids like DHA and EPA have been 
shown to be essential for efficient serotonergic and cholinergic neurotransmission. For 
example, animals deficient in fat-3, the Δ6-desaturase that mediates the first step in the 
conversion of ⍺-linolenic acid (ALA) to EPA and DHA show behavioral defects consistent 
with inefficient serotonin and acetylcholine transmission. Like acox-1 mutants, fat-3 
mutants exhibit egg-laying defects and aldicarb resistance, phenotypes that can be 
rescued with exogenous supplementation of arachidonic acid and docosahexaenoic acid 
[185]. Though the precise mechanisms remain unclear, modulation of neuronal PUFA 
composition seems to influence synaptic vesicle formation and fusion at synaptic 
terminals in turn altering neurotransmission.  It is possible that loss of ACOX-1 alters the 
composition of neuronal PUFAs in turn, causing behavioral phenotypes due to altered  
serotonergic and cholinergic release. The role of PUFAs in mediating the behavioral 
deficits of acox-1 mutants should be more carefully assessed. Dose response 
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experiments with each PUFA should be conducted to understand the ability of each PUFA 
to rescue the phenotypes of acox-1 mutants. As PUFAs serve as essential precursors to 
numerous signaling molecules including NAEs, sphingolipids and eicosanoids, 
experiments with unmetabolizable variants of each PUFA could be a starting place to 
disentangle the contributions of the PUFAs themselves from their derivatives. 
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Figure 4.1 ACOX-1-mediated regulation of serotonergic feeding responses 
requires the EGL-2 K+ channels 
(A) Body Cavity Neurons are required for ACOX-1 to modulate serotonergic feeding 
responses. AQR, PQR and URX neurons were genetically ablated using a gain-of-function 
allele of the EGL-1 caspase. Pharyngeal pumping rates of CX7102 (URX dead) and acox-
1(ok2257); CX7102 animals treated with vehicle or 5mM 5HT. Error bars indicate +/- SEM 
from mean, n=10 animals per condition. *p<0.05, *** p < 0.001,  ANOVA (Tukey)  
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Figure 4.2 ACOX-1, CPT-6 and Body Cavity Neurons regulate acetylcholine 
signaling 
(A, B) Aldicarb induced paralysis assay suggests that acetylcholine signaling may be 
reduced in acox-1, aak-2;acox-1, cpt-6 and URX dead animals (CX7102) Animals were 
placed on plates containing 1mM of the acetylcholinesterase inhibitor Aldicarb. Animals 
were observed and scored as moving or paralyzed every 30 minutes.    
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Figure 4.3 Loss of acox-1 and cpt-6 reduces acetylcholine but not choline levels 
 (A) Pharyngeal pumping rates of wildtype and aak-2 animals treated with vehicle or 1mM 
atropine for one hour. . Error bars indicate +/- SEM from mean, n=10 animals per 
condition. (B) Pharyngeal pumping rates of wildtype and acox-1;aak-2 animals treated with 
vehicle or 1mM arecoline for one hour. Error bars indicate +/- SEM from mean, n=10 
animals per condition  
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Figure 4.4 Inhibition of muscarinic acetylcholine signaling suppresses elevated 
feeding responses of aak-2 mutants  
 (A) Pharyngeal pumping rates of wildtype and aak-2 animals treated with vehicle or 1mM 
atropine for one hour. . Error bars indicate +/- SEM from mean, n=10 animals per 
condition. (B) Pharyngeal pumping rates of wildtype and acox-1;aak-2 animals treated with 
vehicle or 1mM arecoline for one hour. Error bars indicate +/- SEM from mean, n=10 
animals per condition  
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Figure 4.5 RNAi inactivation of fatty acid amide hydrolase (faah-1) stimulates 
feeding responses in a serotonin dependent manner 
 (A) Pharyngeal pumping rates of wildtype and aak-2;acox-1 animals treated with vector or 
faah-1 RNAi. Error bars indicate +/- SEM from mean, n=8 animals per condition. (B) 
Pharyngeal pumping rates of wildtype, acox-1 and tph-1 animals treated with vector or 
faah-1 RNAi. Error bars indicate +/- SEM from mean, n=10 animals per condition. *** p < 
0.001, ANOVA (Tukey).  
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Figure 4.6 Exogenous omega-3 fatty acid derivatives elevate feeding rates of 
wildtype and acox-1 mutants 
 (A) Animals were grown from L1s on plates containing 200µM of each fatty acid before 
assessing pharyngeal pumping rates of day 1 adults. Error bars indicate +/- SEM from 
mean, n=5 animals per condition. Oleoylethanolamine (OEA), palmitoylethanolamine 
(PEA), arachidonoyl ethanolamine (AEA), docosahexaenoyl ethanolamine (DHEA), 
linoleoyl ethanolamine (LEA), arachidonic acid (AA), docosahexaenoic acid (DHA), 
eicosapentaenoyl ethanolamine (EPEA).  
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